Peter Conn
Last active: 4/15/2019

Profile

The primary focus of research in our laboratory is to develop a detailed understanding of the cellular and molecular mechanisms by which transient activation of neurotransmitter receptors can induce long-lasting changes in neuronal excitability and synaptic transmission. Such lasting changes in neuronal function are likely to play an important role in a number of normal physiological processes, ranging from acute regulation of animal behavior to more lasting processes such as formation of long-term memory. In addition, these persistent changes are critical for development of a variety of chronic pathological conditions including, Parkinson's disease, schizophrenia epilepsy, drug dependence and other neurological and psychiatric disorders. Generally, neurotransmitters bring about such lasting changes in properties of cells by stimulating formation of intracellular second messengers and activating protein kinases that then alter the properties of key intracellular regulatory proteins. Thus, we have focused our efforts on the roles of G-protein-coupled receptors (GPCRs) and related second messenger/protein kinase systems in regulating neuronal function. We apply a highly multidisciplinary approach to answer these questions and employ a combination of biochemical, imaging, immunological, and molecular biological techniques to study neuromodulation. In all of our studies, our ultimate goal is to understand the impact of cellular and molecular changes to changes in intact neuronal networks and animal behavior that ultimately impact CNS disorders. Thus, we also employ a range of techniques in behavioral and systems neuroscience By developing this range of understanding, we hope to develop novel strategies for treatment of neurological and psychiatric disorders. We are especially interested in schizophrenia and Parkinson's disease. While our interests in neuromodulation and G protein-mediated signaling are broad, in recent years we have focused primary attention on the physiological roles of a recently discovered family of G protein-coupled glutamate receptors termed metabotropic glutamate receptors (mGluRs). At a circuit level, we have placed a major emphasis on the roles of mGluRs in regulating transmission through the hippocampal formation and in through basal ganglia circuits involved in regulation of motor function and processing of information flow to the cortex. In addition to understanding the roles of mGluRs and other GPCRs in regulating transmission through these circuits, we are placing a significant effort on understanding the precise molecular mechanisms by which GPCRs and signaling cascades activated by these receptors modulate cell excitability and synaptic transmission. These studies are largely focused on identifying protein kinases and phosphatases involved in specific effects, substrates and phosphorylation sites involved, and the impact of such posttranslational changes on protein function. Finally, we are making rapid progress understanding the impact of these changes at a behavioral level. These studies are having a major impact on our understanding of the cellular and systems level mechanisms involved in regulation of complex aspects of animal behavior and disorders of the central nervous system.

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. M muscarinic activation induces long-lasting increase in intrinsic excitability of striatal projection neurons. Lv X, Dickerson JW, Rook JM, Lindsley CW, Conn PJ, Xiang Z (2017) Neuropharmacology : 209-222
    › Primary publication · 28336323 (PubMed) · PMC5501169 (PubMed Central)
  2. Discovery of VU0467485/AZ13713945: An M PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia. Wood MR, Noetzel MJ, Melancon BJ, Poslusney MS, Nance KD, Hurtado MA, Luscombe VB, Weiner RL, Rodriguez AL, Lamsal A, Chang S, Bubser M, Blobaum AL, Engers DW, Niswender CM, Jones CK, Brandon NJ, Wood MW, Duggan ME, Conn PJ, Bridges TM, Lindsley CW (2017) ACS Med Chem Lett 8(2): 233-238
    › Primary publication · 28197318 (PubMed) · PMC5304297 (PubMed Central)
  3. mGluR2 versus mGluR3 Metabotropic Glutamate Receptors in Primate Dorsolateral Prefrontal Cortex: Postsynaptic mGluR3 Strengthen Working Memory Networks. Jin LE, Wang M, Galvin VC, Lightbourne TC, Conn PJ, Arnsten AFT, Paspalas CD (2018) Cereb Cortex 28(3): 974-987
    › Primary publication · 28108498 (PubMed) · PMC5974790 (PubMed Central)
  4. Diverse Effects on M Signaling and Adverse Effect Liability within a Series of M Ago-PAMs. Rook JM, Abe M, Cho HP, Nance KD, Luscombe VB, Adams JJ, Dickerson JW, Remke DH, Garcia-Barrantes PM, Engers DW, Engers JL, Chang S, Foster JJ, Blobaum AL, Niswender CM, Jones CK, Conn PJ, Lindsley CW (2017) ACS Chem Neurosci 8(4): 866-883
    › Primary publication · 28001356 (PubMed) · PMC5460155 (PubMed Central)
  5. Challenges in the development of an M PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs. Wood MR, Noetzel MJ, Poslusney MS, Melancon BJ, Tarr JC, Lamsal A, Chang S, Luscombe VB, Weiner RL, Cho HP, Bubser M, Jones CK, Niswender CM, Wood MW, Engers DW, Brandon NJ, Duggan ME, Conn PJ, Bridges TM, Lindsley CW (2017) Bioorg Med Chem Lett 27(2): 171-175
    › Primary publication · 27939174 (PubMed) · PMC5340297 (PubMed Central)
  6. Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release. Foster DJ, Wilson JM, Remke DH, Mahmood MS, Uddin MJ, Wess J, Patel S, Marnett LJ, Niswender CM, Jones CK, Xiang Z, Lindsley CW, Rook JM, Conn PJ (2016) Neuron 91(6): 1244-1252
    › Primary publication · 27618677 (PubMed) · PMC5033724 (PubMed Central)
  7. Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M PAM VU6004256. Grannan MD, Mielnik CA, Moran SP, Gould RW, Ball J, Lu Z, Bubser M, Ramsey AJ, Abe M, Cho HP, Nance KD, Blobaum AL, Niswender CM, Conn PJ, Lindsley CW, Jones CK (2016) ACS Chem Neurosci 7(12): 1706-1716
    › Primary publication · 27617634 (PubMed) · PMC5231396 (PubMed Central)
  8. Ligand-based virtual screen for the discovery of novel M5 inhibitor chemotypes. Geanes AR, Cho HP, Nance KD, McGowan KM, Conn PJ, Jones CK, Meiler J, Lindsley CW (2016) Bioorg Med Chem Lett 26(18): 4487-4491
    › Primary publication · 27503678 (PubMed) · PMC4996684 (PubMed Central)
  9. Discovery and SAR of a novel series of potent, CNS penetrant M4 PAMs based on a non-enolizable ketone core: Challenges in disposition. Wood MR, Noetzel MJ, Tarr JC, Rodriguez AL, Lamsal A, Chang S, Foster JJ, Smith E, Chase P, Hodder PS, Engers DW, Niswender CM, Brandon NJ, Wood MW, Duggan ME, Conn PJ, Bridges TM, Lindsley CW (2016) Bioorg Med Chem Lett 26(17): 4282-6
    › Primary publication · 27476142 (PubMed) · PMC4987221 (PubMed Central)
  10. Increased Metabotropic Glutamate Receptor 5 Signaling Underlies Obsessive-Compulsive Disorder-like Behavioral and Striatal Circuit Abnormalities in Mice. Ade KK, Wan Y, Hamann HC, O'Hare JK, Guo W, Quian A, Kumar S, Bhagat S, Rodriguiz RM, Wetsel WC, Conn PJ, Dzirasa K, Huber KM, Calakos N (2016) Biol Psychiatry 80(7): 522-33
    › Primary publication · 27436084 (PubMed) · PMC5536332 (PubMed Central)
  11. Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery. Sengmany K, Singh J, Stewart GD, Conn PJ, Christopoulos A, Gregory KJ (2017) Neuropharmacology : 60-72
    › Primary publication · 27392634 (PubMed) · PMC5217481 (PubMed Central)
  12. The Role of mGlu Receptors in Hippocampal Plasticity Deficits in Neurological and Psychiatric Disorders: Implications for Allosteric Modulators as Novel Therapeutic Strategies. Senter RK, Ghoshal A, Walker AG, Xiang Z, Niswender CM, Conn PJ (2016) Curr Neuropharmacol 14(5): 455-73
    › Primary publication · 27296640 (PubMed) · PMC4983746 (PubMed Central)
  13. Discovery and characterization of a novel series of N-phenylsulfonyl-1H-pyrrole picolinamides as positive allosteric modulators of the metabotropic glutamate receptor 4 (mGlu4). Gogliotti RD, Blobaum AL, Morrison RM, Daniels JS, Salovich JM, Cheung YY, Rodriguez AL, Loch MT, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR (2016) Bioorg Med Chem Lett 26(13): 2984-2987
    › Primary publication · 27234146 (PubMed) · PMC4955388 (PubMed Central)
  14. Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine core. Wood MR, Noetzel MJ, Engers JL, Bollinger KA, Melancon BJ, Tarr JC, Han C, West M, Gregro AR, Lamsal A, Chang S, Ajmera S, Smith E, Chase P, Hodder PS, Bubser M, Jones CK, Hopkins CR, Emmitte KA, Niswender CM, Wood MW, Duggan ME, Conn PJ, Bridges TM, Lindsley CW (2016) Bioorg Med Chem Lett 26(13): 3029-3033
    › Primary publication · 27185330 (PubMed) · PMC4955361 (PubMed Central)
  15. Further optimization of the M1 PAM VU0453595: Discovery of novel heterobicyclic core motifs with improved CNS penetration. Panarese JD, Cho HP, Adams JJ, Nance KD, Garcia-Barrantes PM, Chang S, Morrison RD, Blobaum AL, Niswender CM, Stauffer SR, Conn PJ, Lindsley CW (2016) Bioorg Med Chem Lett 26(15): 3822-5
    › Primary publication · 27173801 (PubMed) · PMC5082649 (PubMed Central)
  16. Discovery of 3-aminopicolinamides as metabotropic glutamate receptor subtype 4 (mGlu4) positive allosteric modulator warheads engendering CNS exposure and in vivo efficacy. Gogliotti RD, Engers DW, Garcia-Barrantes PM, Panarese JD, Gentry PR, Blobaum AL, Morrison RD, Daniels JS, Thompson AD, Jones CK, Conn PJ, Niswender CM, Lindsley CW, Hopkins CR (2016) Bioorg Med Chem Lett 26(12): 2915-2919
    › Primary publication · 27131990 (PubMed) · PMC4899947 (PubMed Central)
  17. Clickable Photoaffinity Ligands for Metabotropic Glutamate Receptor 5 Based on Select Acetylenic Negative Allosteric Modulators. Gregory KJ, Velagaleti R, Thal DM, Brady RM, Christopoulos A, Conn PJ, Lapinsky DJ (2016) ACS Chem Biol 11(7): 1870-9
    › Primary publication · 27115427 (PubMed) · PMC4981245 (PubMed Central)
  18. Re-exploration of the mGlu₁ PAM Ro 07-11401 scaffold: Discovery of analogs with improved CNS penetration despite steep SAR. Garcia-Barrantes PM, Cho HP, Starr TM, Blobaum AL, Niswender CM, Conn PJ, Lindsley CW (2016) Bioorg Med Chem Lett 26(9): 2289-92
    › Primary publication · 27013388 (PubMed) · PMC4833523 (PubMed Central)
  19. N-Alkylpyrido[1',2':1,5]pyrazolo-[4,3-d]pyrimidin-4-amines: A new series of negative allosteric modulators of mGlu1/5 with CNS exposure in rodents. Felts AS, Rodriguez AL, Morrison RD, Venable DF, Blobaum AL, Byers FW, Daniels JS, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Emmitte KA (2016) Bioorg Med Chem Lett 26(8): 1894-900
    › Primary publication · 26988308 (PubMed) · PMC4824313 (PubMed Central)
  20. Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 3. Engineering plasma stability by discovery and optimization of isoindolinone analogs. Garcia-Barrantes PM, Cho HP, Blobaum AL, Niswender CM, Conn PJ, Lindsley CW (2016) Bioorg Med Chem Lett 26(8): 1869-72
    › Primary publication · 26988302 (PubMed) · PMC4823774 (PubMed Central)
  21. Novel PAMs Targeting NMDAR GluN2A Subunit. Xiang Z, Conn PJ (2016) Neuron 89(5): 884-6
    › Primary publication · 26938436 (PubMed) · PMC4793964 (PubMed Central)
  22. mGlu5 positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome. Gogliotti RG, Senter RK, Rook JM, Ghoshal A, Zamorano R, Malosh C, Stauffer SR, Bridges TM, Bartolome JM, Daniels JS, Jones CK, Lindsley CW, Conn PJ, Niswender CM (2016) Hum Mol Genet 25(10): 1990-2004
    › Primary publication · 26936821 (PubMed) · PMC5062588 (PubMed Central)
  23. Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors. Lindsley CW, Emmitte KA, Hopkins CR, Bridges TM, Gregory KJ, Niswender CM, Conn PJ (2016) Chem Rev 116(11): 6707-41
    › Primary publication · 26882314 (PubMed) · PMC4988345 (PubMed Central)
  24. The Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator ADX88178 Inhibits Inflammatory Responses in Primary Microglia. Ponnazhagan R, Harms AS, Thome AD, Jurkuvenaite A, Gogliotti R, Niswender CM, Conn PJ, Standaert DG (2016) J Neuroimmune Pharmacol 11(2): 231-7
    › Primary publication · 26872456 (PubMed) · PMC4848139 (PubMed Central)
  25. Lead optimization of the VU0486321 series of mGlu(1) PAMs. Part 2: SAR of alternative 3-methyl heterocycles and progress towards an in vivo tool. Garcia-Barrantes PM, Cho HP, Metts AM, Blobaum AL, Niswender CM, Conn PJ, Lindsley CW (2016) Bioorg Med Chem Lett 26(3): 751-756
    › Primary publication · 26778256 (PubMed) · PMC4794757 (PubMed Central)
  26. An mGlu5-Positive Allosteric Modulator Rescues the Neuroplasticity Deficits in a Genetic Model of NMDA Receptor Hypofunction in Schizophrenia. Balu DT, Li Y, Takagi S, Presti KT, Ramikie TS, Rook JM, Jones CK, Lindsley CW, Conn PJ, Bolshakov VY, Coyle JT (2016) Neuropsychopharmacology 41(8): 2052-61
    › Primary publication · 26741285 (PubMed) · PMC4908650 (PubMed Central)
  27. Preliminary investigation of 6,7-dihydropyrazolo[1,5-a]pyrazin-4-one derivatives as a novel series of mGlu5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia. Conde-Ceide S, Alcázar J, Alonso de Diego SA, López S, Martín-Martín ML, Martínez-Viturro CM, Pena MA, Tong HM, Lavreysen H, Mackie C, Bridges TM, Daniels JS, Niswender CM, Jones CK, Macdonald GJ, Steckler T, Conn PJ, Stauffer SR, Lindsley CW, Bartolomé-Nebreda JM (2016) Bioorg Med Chem Lett 26(2): 429-434
    › Primary publication · 26684851 (PubMed) · PMC4835042 (PubMed Central)
  28. Pharmacological Treatments for Autism Spectrum Disorder: Will Emerging Approaches Yield New Treatments? Gogliotti RG, Conn PJ (2016) Neuropsychopharmacology 41(1): 376-7
    › Primary publication · 26657955 (PubMed) · PMC4677143 (PubMed Central)
  29. Neurobiological Insights from mGlu Receptor Allosteric Modulation. O'Brien DE, Conn PJ (2016) Int J Neuropsychopharmacol 19(5)
    › Primary publication · 26647381 (PubMed) · PMC4886670 (PubMed Central)
  30. Measurement of Blood Volume in Adult Rhesus Macaques (Macaca mulatta). Hobbs TR, Blue SW, Park BS, Greisel JJ, Conn PM, Pau FK (2015) J Am Assoc Lab Anim Sci 54(6): 687-93
    › Primary publication · 26632777 (PubMed) · PMC4671783 (PubMed Central)
  31. M1 and M3 muscarinic receptors may play a role in the neurotoxicity of anhydroecgonine methyl ester, a cocaine pyrolysis product. Garcia RC, Dati LM, Torres LH, da Silva MA, Udo MS, Abdalla FM, da Costa JL, Gorjão R, Afeche SC, Yonamine M, Niswender CM, Conn PJ, Camarini R, Sandoval MR, Marcourakis T (2015) Sci Rep : 17555
    › Primary publication · 26626425 (PubMed) · PMC4667193 (PubMed Central)
  32. State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects. Gould RW, Nedelcovych MT, Gong X, Tsai E, Bubser M, Bridges TM, Wood MR, Duggan ME, Brandon NJ, Dunlop J, Wood MW, Ivarsson M, Noetzel MJ, Daniels JS, Niswender CM, Lindsley CW, Conn PJ, Jones CK (2016) Neuropharmacology : 244-53
    › Primary publication · 26617071 (PubMed) · PMC4809053 (PubMed Central)
  33. M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia. Shen W, Plotkin JL, Francardo V, Ko WK, Xie Z, Li Q, Fieblinger T, Wess J, Neubig RR, Lindsley CW, Conn PJ, Greengard P, Bezard E, Cenci MA, Surmeier DJ (2015) Neuron 88(4): 762-73
    › Primary publication · 26590347 (PubMed) · PMC4864040 (PubMed Central)
  34. Design of 4-Oxo-1-aryl-1,4-dihydroquinoline-3-carboxamides as Selective Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 2. Felts AS, Rodriguez AL, Smith KA, Engers JL, Morrison RD, Byers FW, Blobaum AL, Locuson CW, Chang S, Venable DF, Niswender CM, Daniels JS, Conn PJ, Lindsley CW, Emmitte KA (2015) J Med Chem 58(22): 9027-40
    › Primary publication · 26524606 (PubMed) · PMC4817271 (PubMed Central)
  35. Changes in BQCA Allosteric Modulation of [(3)H]NMS Binding to Human Cortex within Schizophrenia and by Divalent Cations. Dean B, Hopper S, Conn PJ, Scarr E (2016) Neuropsychopharmacology 41(6): 1620-8
    › Primary publication · 26511338 (PubMed) · PMC4832025 (PubMed Central)
  36. Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice. Pancani T, Foster DJ, Moehle MS, Bichell TJ, Bradley E, Bridges TM, Klar R, Poslusney M, Rook JM, Daniels JS, Niswender CM, Jones CK, Wood MR, Bowman AB, Lindsley CW, Xiang Z, Conn PJ (2015) Proc Natl Acad Sci U S A 112(45): 14078-83
    › Primary publication · 26508634 (PubMed) · PMC4653197 (PubMed Central)
  37. VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo Efficacy. Nickols HH, Yuh JP, Gregory KJ, Morrison RD, Bates BS, Stauffer SR, Emmitte KA, Bubser M, Peng W, Nedelcovych MT, Thompson A, Lv X, Xiang Z, Daniels JS, Niswender CM, Lindsley CW, Jones CK, Conn PJ (2016) J Pharmacol Exp Ther 356(1): 123-36
    › Primary publication · 26503377 (PubMed) · PMC4702078 (PubMed Central)
  38. On Extrapolating Past the Range of Observed Data When Making Statistical Predictions in Ecology. Conn PB, Johnson DS, Boveng PL (2015) PLoS One 10(10): e0141416
    › Primary publication · 26496358 (PubMed) · PMC4619888 (PubMed Central)
  39. Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 1: SAR of modifications to the central aryl core. Garcia-Barrantes PM, Cho HP, Blobaum AL, Niswender CM, Conn PJ, Lindsley CW (2015) Bioorg Med Chem Lett 25(22): 5107-10
    › Primary publication · 26476971 (PubMed) · PMC4758672 (PubMed Central)
  40. Acyl dihydropyrazolo[1,5-a]pyrimidinones as metabotropic glutamate receptor 5 positive allosteric modulators. Malosh C, Turlington M, Bridges TM, Rook JM, Noetzel MJ, Vinson PN, Steckler T, Lavreysen H, Mackie C, Bartolomé-Nebreda JM, Conde-Ceide S, Martínez-Viturro CM, Piedrafita M, Sánchez-Casado MR, Macdonald GJ, Daniels JS, Jones CK, Niswender CM, Conn PJ, Lindsley CW, Stauffer SR (2015) Bioorg Med Chem Lett 25(22): 5115-20
    › Primary publication · 26475522 (PubMed) · PMC4634704 (PubMed Central)
  41. Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics. Garcia-Barrantes PM, Cho HP, Niswender CM, Byers FW, Locuson CW, Blobaum AL, Xiang Z, Rook JM, Conn PJ, Lindsley CW (2015) J Med Chem 58(20): 7959-71
    › Primary publication · 26426481 (PubMed) · PMC4839290 (PubMed Central)
  42. Tackling reproducibility in academic preclinical drug discovery. Frye SV, Arkin MR, Arrowsmith CH, Conn PJ, Glicksman MA, Hull-Ryde EA, Slusher BS (2015) Nat Rev Drug Discov 14(11): 733-4
    › Primary publication · 26388229 (PubMed)
  43. Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents. Engers JL, Rodriguez AL, Konkol LC, Morrison RD, Thompson AD, Byers FW, Blobaum AL, Chang S, Venable DF, Loch MT, Niswender CM, Daniels JS, Jones CK, Conn PJ, Lindsley CW, Emmitte KA (2015) J Med Chem 58(18): 7485-500
    › Primary publication · 26335039 (PubMed) · PMC4809247 (PubMed Central)
  44. Partial mGlu₅ Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects. Gould RW, Amato RJ, Bubser M, Joffe ME, Nedelcovych MT, Thompson AD, Nickols HH, Yuh JP, Zhan X, Felts AS, Rodriguez AL, Morrison RD, Byers FW, Rook JM, Daniels JS, Niswender CM, Conn PJ, Emmitte KA, Lindsley CW, Jones CK (2016) Neuropsychopharmacology 41(4): 1166-78
    › Primary publication · 26315507 (PubMed) · PMC4748441 (PubMed Central)
  45. A Screen of Approved Drugs Identifies the Androgen Receptor Antagonist Flutamide and Its Pharmacologically Active Metabolite 2-Hydroxy-Flutamide as Heterotropic Activators of Cytochrome P450 3A In Vitro and In Vivo. Blobaum AL, Byers FW, Bridges TM, Locuson CW, Conn PJ, Lindsley CW, Daniels JS (2015) Drug Metab Dispos 43(11): 1718-26
    › Primary publication · 26265743 (PubMed) · PMC4613951 (PubMed Central)
  46. Further optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compound. Zhou Y, Malosh C, Conde-Ceide S, Martínez-Viturro CM, Alcázar J, Lavreysen H, Mackie C, Bridges TM, Daniels JS, Niswender CM, Jones CK, Macdonald GJ, Steckler T, Conn PJ, Stauffer SR, Bartolomé-Nebreda JM, Lindsley CW (2015) Bioorg Med Chem Lett 25(17): 3515-9
    › Primary publication · 26183084 (PubMed) · PMC4535329 (PubMed Central)
  47. Role for the M1 Muscarinic Acetylcholine Receptor in Top-Down Cognitive Processing Using a Touchscreen Visual Discrimination Task in Mice. Gould RW, Dencker D, Grannan M, Bubser M, Zhan X, Wess J, Xiang Z, Locuson C, Lindsley CW, Conn PJ, Jones CK (2015) ACS Chem Neurosci 6(10): 1683-95
    › Primary publication · 26176846 (PubMed) · PMC4830475 (PubMed Central)
  48. Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia. Conde-Ceide S, Martínez-Viturro CM, Alcázar J, Garcia-Barrantes PM, Lavreysen H, Mackie C, Vinson PN, Rook JM, Bridges TM, Daniels JS, Megens A, Langlois X, Drinkenburg WH, Ahnaou A, Niswender CM, Jones CK, Macdonald GJ, Steckler T, Conn PJ, Stauffer SR, Bartolomé-Nebreda JM, Lindsley CW (2015) ACS Med Chem Lett 6(6): 716-20
    › Primary publication · 26157544 (PubMed) · PMC4492464 (PubMed Central)
  49. Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model. Ghoshal A, Rook JM, Dickerson JW, Roop GN, Morrison RD, Jalan-Sakrikar N, Lamsal A, Noetzel MJ, Poslusney MS, Wood MR, Melancon BJ, Stauffer SR, Xiang Z, Daniels JS, Niswender CM, Jones CK, Lindsley CW, Conn PJ (2016) Neuropsychopharmacology 41(2): 598-610
    › Primary publication · 26108886 (PubMed) · PMC5130135 (PubMed Central)
  50. Assay strategies for identification of therapeutic leads that target protein trafficking. Conn PM, Spicer TP, Scampavia L, Janovick JA (2015) Trends Pharmacol Sci 36(8): 498-505
    › Primary publication · 26067100 (PubMed) · PMC4532603 (PubMed Central)
  51. Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes. Schreiber SL, Kotz JD, Li M, Aubé J, Austin CP, Reed JC, Rosen H, White EL, Sklar LA, Lindsley CW, Alexander BR, Bittker JA, Clemons PA, de Souza A, Foley MA, Palmer M, Shamji AF, Wawer MJ, McManus O, Wu M, Zou B, Yu H, Golden JE, Schoenen FJ, Simeonov A, Jadhav A, Jackson MR, Pinkerton AB, Chung TD, Griffin PR, Cravatt BF, Hodder PS, Roush WR, Roberts E, Chung DH, Jonsson CB, Noah JW, Severson WE, Ananthan S, Edwards B, Oprea TI, Conn PJ, Hopkins CR, Wood MR, Stauffer SR, Emmitte KA, NIH Molecular Libraries Project Team (2015) Cell 161(6): 1252-65
    › Primary publication · 26046436 (PubMed) · PMC4564295 (PubMed Central)
  52. Activation of Metabotropic Glutamate Receptor 7 Is Required for Induction of Long-Term Potentiation at SC-CA1 Synapses in the Hippocampus. Klar R, Walker AG, Ghose D, Grueter BA, Engers DW, Hopkins CR, Lindsley CW, Xiang Z, Conn PJ, Niswender CM (2015) J Neurosci 35(19): 7600-15
    › Primary publication · 25972184 (PubMed) · PMC4429158 (PubMed Central)
  53. The First 50 Years of Molecular Pharmacology. Brown JH, Catterall WA, Conn PJ, Cull-Candy SG, Dingledine R, Harden TK, Insel PA, Milligan G, Traynelis SF (2015) Mol Pharmacol 88(1): 139-40
    › Primary publication · 25943115 (PubMed)
  54. Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents. Rook JM, Xiang Z, Lv X, Ghoshal A, Dickerson JW, Bridges TM, Johnson KA, Foster DJ, Gregory KJ, Vinson PN, Thompson AD, Byun N, Collier RL, Bubser M, Nedelcovych MT, Gould RW, Stauffer SR, Daniels JS, Niswender CM, Lavreysen H, Mackie C, Conde-Ceide S, Alcazar J, Bartolomé-Nebreda JM, Macdonald GJ, Talpos JC, Steckler T, Jones CK, Lindsley CW, Conn PJ (2015) Neuron 86(4): 1029-1040
    › Primary publication · 25937172 (PubMed) · PMC4443790 (PubMed Central)
  55. Application of Parallel Multiparametric Cell-Based FLIPR Detection Assays for the Identification of Modulators of the Muscarinic Acetylcholine Receptor 4 (M4). Smith E, Chase P, Niswender CM, Utley TJ, Sheffler DJ, Noetzel MJ, Lamsal A, Wood MR, Conn PJ, Lindsley CW, Madoux F, Acosta M, Scampavia L, Spicer T, Hodder P (2015) J Biomol Screen 20(7): 858-68
    › Primary publication · 25877150 (PubMed) · PMC4659430 (PubMed Central)
  56. Pharmacoperones: targeting therapeutics toward diseases caused by protein misfolding. Ulloa-Aguirre A, Zariñán T, Conn PM (2015) Rev Invest Clin 67(1): 15-9
    › Primary publication · 25857579 (PubMed)
  57. The hippocampo-prefrontal pathway: a possible therapeutic target for negative and cognitive symptoms of schizophrenia. Ghoshal A, Conn PJ (2015) Future Neurol 10(2): 115-128
    › Primary publication · 25825588 (PubMed) · PMC4376007 (PubMed Central)
  58. Molecular Insights into Metabotropic Glutamate Receptor Allosteric Modulation. Gregory KJ, Conn PJ (2015) Mol Pharmacol 88(1): 188-202
    › Primary publication · 25808929 (PubMed) · PMC4468636 (PubMed Central)
  59. Effects of VU0410120, a novel GlyT1 inhibitor, on measures of sociability, cognition and stereotypic behaviors in a mouse model of autism. Burket JA, Benson AD, Green TL, Rook JM, Lindsley CW, Conn PJ, Deutsch SI (2015) Prog Neuropsychopharmacol Biol Psychiatry : 10-7
    › Primary publication · 25784602 (PubMed)
  60. Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist. Iderberg H, Maslava N, Thompson AD, Bubser M, Niswender CM, Hopkins CR, Lindsley CW, Conn PJ, Jones CK, Cenci MA (2015) Neuropharmacology : 121-9
    › Primary publication · 25749357 (PubMed) · PMC4466038 (PubMed Central)
  61. Development of a phenotypic high-content assay to identify pharmacoperone drugs for the treatment of primary hyperoxaluria type 1 by high-throughput screening. Madoux F, Janovick JA, Smithson D, Fargue S, Danpure CJ, Scampavia L, Chen YT, Spicer TP, Conn PM (2015) Assay Drug Dev Technol 13(1): 16-24
    › Primary publication · 25710543 (PubMed)
  62. Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5). Martín-Martín ML, Bartolomé-Nebreda JM, Conde-Ceide S, Alonso de Diego SA, López S, Martínez-Viturro CM, Tong HM, Lavreysen H, Macdonald GJ, Steckler T, Mackie C, Bridges TM, Daniels JS, Niswender CM, Noetzel MJ, Jones CK, Conn PJ, Lindsley CW, Stauffer SR (2015) Bioorg Med Chem Lett 25(6): 1310-7
    › Primary publication · 25683622 (PubMed) · PMC4399811 (PubMed Central)
  63. Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction. Walker AG, Wenthur CJ, Xiang Z, Rook JM, Emmitte KA, Niswender CM, Lindsley CW, Conn PJ (2015) Proc Natl Acad Sci U S A 112(4): 1196-201
    › Primary publication · 25583490 (PubMed) · PMC4313856 (PubMed Central)
  64. Further optimization of the M5 NAM MLPCN probe ML375: tactics and challenges. Kurata H, Gentry PR, Kokubo M, Cho HP, Bridges TM, Niswender CM, Byers FW, Wood MR, Daniels JS, Conn PJ, Lindsley CW (2015) Bioorg Med Chem Lett 25(3): 690-4
    › Primary publication · 25542588 (PubMed) · PMC4535335 (PubMed Central)
  65. Gonadotrope-specific deletion of Dicer results in severely suppressed gonadotropins and fertility defects. Wang H, Graham I, Hastings R, Gunewardena S, Brinkmeier ML, Conn PM, Camper SA, Kumar TR (2015) J Biol Chem 290(5): 2699-714
    › Primary publication · 25525274 (PubMed) · PMC4317015 (PubMed Central)
  66. Group I and group II metabotropic glutamate receptor allosteric modulators as novel potential antipsychotics. Walker AG, Conn PJ (2015) Curr Opin Pharmacol : 40-5
    › Primary publication · 25462291 (PubMed) · PMC4318747 (PubMed Central)
  67. Discovery and SAR of muscarinic receptor subtype 1 (M1) allosteric activators from a molecular libraries high throughput screen. Part 1: 2,5-dibenzyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones as positive allosteric modulators. Han C, Chatterjee A, Noetzel MJ, Panarese JD, Smith E, Chase P, Hodder P, Niswender C, Conn PJ, Lindsley CW, Stauffer SR (2015) Bioorg Med Chem Lett 25(2): 384-8
    › Primary publication · 25435150 (PubMed) · PMC4278958 (PubMed Central)
  68. Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profiles. Rook JM, Tantawy MN, Ansari MS, Felts AS, Stauffer SR, Emmitte KA, Kessler RM, Niswender CM, Daniels JS, Jones CK, Lindsley CW, Conn PJ (2015) Neuropsychopharmacology 40(3): 755-65
    › Primary publication · 25241804 (PubMed) · PMC4289965 (PubMed Central)
  69. Identification of positive allosteric modulators VU0155094 (ML397) and VU0422288 (ML396) reveals new insights into the biology of metabotropic glutamate receptor 7. Jalan-Sakrikar N, Field JR, Klar R, Mattmann ME, Gregory KJ, Zamorano R, Engers DW, Bollinger SR, Weaver CD, Days EL, Lewis LM, Utley TJ, Hurtado M, Rigault D, Acher F, Walker AG, Melancon BJ, Wood MR, Lindsley CW, Conn PJ, Xiang Z, Hopkins CR, Niswender CM (2014) ACS Chem Neurosci 5(12): 1221-37
    › Primary publication · 25225882 (PubMed) · PMC4306484 (PubMed Central)
  70. Anticholinergic drugs rescue synaptic plasticity in DYT1 dystonia: role of M1 muscarinic receptors. Maltese M, Martella G, Madeo G, Fagiolo I, Tassone A, Ponterio G, Sciamanna G, Burbaud P, Conn PJ, Bonsi P, Pisani A (2014) Mov Disord 29(13): 1655-65
    › Primary publication · 25195914 (PubMed) · PMC4216601 (PubMed Central)
  71. Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Conn PJ, Lindsley CW, Meiler J, Niswender CM (2014) Nat Rev Drug Discov 13(9): 692-708
    › Primary publication · 25176435 (PubMed) · PMC4208620 (PubMed Central)
  72. Development of a highly potent, novel M5 positive allosteric modulator (PAM) demonstrating CNS exposure: 1-((1H-indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380). Gentry PR, Kokubo M, Bridges TM, Noetzel MJ, Cho HP, Lamsal A, Smith E, Chase P, Hodder PS, Niswender CM, Daniels JS, Conn PJ, Lindsley CW, Wood MR (2014) J Med Chem 57(18): 7804-10
    › Primary publication · 25147929 (PubMed) · PMC4175000 (PubMed Central)
  73. Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents. Bubser M, Bridges TM, Dencker D, Gould RW, Grannan M, Noetzel MJ, Lamsal A, Niswender CM, Daniels JS, Poslusney MS, Melancon BJ, Tarr JC, Byers FW, Wess J, Duggan ME, Dunlop J, Wood MW, Brandon NJ, Wood MR, Lindsley CW, Conn PJ, Jones CK (2014) ACS Chem Neurosci 5(10): 920-42
    › Primary publication · 25137629 (PubMed) · PMC4324418 (PubMed Central)
  74. Chemical modulation of mutant mGlu1 receptors derived from deleterious GRM1 mutations found in schizophrenics. Cho HP, Garcia-Barrantes PM, Brogan JT, Hopkins CR, Niswender CM, Rodriguez AL, Venable DF, Morrison RD, Bubser M, Daniels JS, Jones CK, Conn PJ, Lindsley CW (2014) ACS Chem Biol 9(10): 2334-46
    › Primary publication · 25137254 (PubMed) · PMC4201332 (PubMed Central)
  75. Novel mGluR5 positive allosteric modulator improves functional recovery, attenuates neurodegeneration, and alters microglial polarization after experimental traumatic brain injury. Loane DJ, Stoica BA, Tchantchou F, Kumar A, Barrett JP, Akintola T, Xue F, Conn PJ, Faden AI (2014) Neurotherapeutics 11(4): 857-69
    › Primary publication · 25096154 (PubMed) · PMC4391388 (PubMed Central)
  76. Modulation of neuronal microcircuit activities within the medial prefrontal cortex by mGluR5 positive allosteric modulator. Pollard M, Bartolome JM, Conn PJ, Steckler T, Shaban H (2014) J Psychopharmacol 28(10): 935-46
    › Primary publication · 25031220 (PubMed) · PMC4356529 (PubMed Central)
  77. Discovery of VU0431316: a negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety. Bates BS, Rodriguez AL, Felts AS, Morrison RD, Venable DF, Blobaum AL, Byers FW, Lawson KP, Daniels JS, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Emmitte KA (2014) Bioorg Med Chem Lett 24(15): 3307-14
    › Primary publication · 24969015 (PubMed) · PMC4090943 (PubMed Central)
  78. A hidden Markov model to identify and adjust for selection bias: an example involving mixed migration strategies. Fieberg JR, Conn PB (2014) Ecol Evol 4(10): 1903-12
    › Primary publication · 24963384 (PubMed) · PMC4063483 (PubMed Central)
  79. Discovery and SAR of a novel series of metabotropic glutamate receptor 5 positive allosteric modulators with high ligand efficiency. Turlington M, Noetzel MJ, Bridges TM, Vinson PN, Steckler T, Lavreysen H, Mackie C, Bartolomé-Nebreda JM, Conde-Ceide S, Tong HM, Macdonald GJ, Daniels JS, Jones CK, Niswender CM, Conn PJ, Lindsley CW, Stauffer SR (2014) Bioorg Med Chem Lett 24(15): 3641-6
    › Primary publication · 24961642 (PubMed) · PMC4234308 (PubMed Central)
  80. Tetrahydronaphthyridine and dihydronaphthyridinone ethers as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu₅). Turlington M, Malosh C, Jacobs J, Manka JT, Noetzel MJ, Vinson PN, Jadhav S, Herman EJ, Lavreysen H, Mackie C, Bartolomé-Nebreda JM, Conde-Ceide S, Martín-Martín ML, Tong HM, López S, MacDonald GJ, Steckler T, Daniels JS, Weaver CD, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Stauffer SR (2014) J Med Chem 57(13): 5620-37
    › Primary publication · 24914612 (PubMed) · PMC4096224 (PubMed Central)
  81. Head-to head comparison of mGlu1 and mGlu5 receptor activation in chronic treatment of absence epilepsy in WAG/Rij rats. D'Amore V, Santolini I, Celli R, Lionetto L, De Fusco A, Simmaco M, van Rijn CM, Vieira E, Stauffer SR, Conn PJ, Bosco P, Nicoletti F, van Luijtelaar G, Ngomba RT (2014) Neuropharmacology : 91-103
    › Primary publication · 24859611 (PubMed) · PMC4356528 (PubMed Central)
  82. A novel class of succinimide-derived negative allosteric modulators of metabotropic glutamate receptor subtype 1 provides insight into a disconnect in activity between the rat and human receptors. Cho HP, Engers DW, Venable DF, Niswender CM, Lindsley CW, Conn PJ, Emmitte KA, Rodriguez AL (2014) ACS Chem Neurosci 5(7): 597-610
    › Primary publication · 24798819 (PubMed) · PMC4102972 (PubMed Central)
  83. Synthesis and SAR of substituted pyrazolo[1,5-a]quinazolines as dual mGlu(2)/mGlu(3) NAMs. Wenthur CJ, Morrison RD, Daniels JS, Conn PJ, Lindsley CW (2014) Bioorg Med Chem Lett 24(12): 2693-8
    › Primary publication · 24794112 (PubMed) · PMC4075068 (PubMed Central)
  84. Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence. Dhanya RP, Sheffler DJ, Dahl R, Davis M, Lee PS, Yang L, Nickols HH, Cho HP, Smith LH, D'Souza MS, Conn PJ, Der-Avakian A, Markou A, Cosford ND (2014) J Med Chem 57(10): 4154-72
    › Primary publication · 24735492 (PubMed) · PMC4033659 (PubMed Central)
  85. Discovery, synthesis and characterization of a highly muscarinic acetylcholine receptor (mAChR)-selective M5-orthosteric antagonist, VU0488130 (ML381): a novel molecular probe. Gentry PR, Kokubo M, Bridges TM, Cho HP, Smith E, Chase P, Hodder PS, Utley TJ, Rajapakse A, Byers F, Niswender CM, Morrison RD, Daniels JS, Wood MR, Conn PJ, Lindsley CW (2014) ChemMedChem 9(8): 1677-82
    › Primary publication · 24692176 (PubMed) · PMC4116439 (PubMed Central)
  86. Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Wu H, Wang C, Gregory KJ, Han GW, Cho HP, Xia Y, Niswender CM, Katritch V, Meiler J, Cherezov V, Conn PJ, Stevens RC (2014) Science 344(6179): 58-64
    › Primary publication · 24603153 (PubMed) · PMC3991565 (PubMed Central)
  87. M5 receptor activation produces opposing physiological outcomes in dopamine neurons depending on the receptor's location. Foster DJ, Gentry PR, Lizardi-Ortiz JE, Bridges TM, Wood MR, Niswender CM, Sulzer D, Lindsley CW, Xiang Z, Conn PJ (2014) J Neurosci 34(9): 3253-62
    › Primary publication · 24573284 (PubMed) · PMC3935086 (PubMed Central)
  88. Identification of specific ligand-receptor interactions that govern binding and cooperativity of diverse modulators to a common metabotropic glutamate receptor 5 allosteric site. Gregory KJ, Nguyen ED, Malosh C, Mendenhall JL, Zic JZ, Bates BS, Noetzel MJ, Squire EF, Turner EM, Rook JM, Emmitte KA, Stauffer SR, Lindsley CW, Meiler J, Conn PJ (2014) ACS Chem Neurosci 5(4): 282-95
    › Primary publication · 24528109 (PubMed) · PMC3990945 (PubMed Central)
  89. M4 mAChR-mediated modulation of glutamatergic transmission at corticostriatal synapses. Pancani T, Bolarinwa C, Smith Y, Lindsley CW, Conn PJ, Xiang Z (2014) ACS Chem Neurosci 5(4): 318-24
    › Primary publication · 24528004 (PubMed) · PMC3990947 (PubMed Central)
  90. Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia. Foster DJ, Choi DL, Conn PJ, Rook JM (2014) Neuropsychiatr Dis Treat : 183-91
    › Primary publication · 24511233 (PubMed) · PMC3913542 (PubMed Central)
  91. Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 2: development of a [3.3.0]-based series and other piperidine bioisosteres. Sheffler DJ, Nedelcovych MT, Williams R, Turner SC, Duerk BB, Robbins MR, Jadhav SB, Niswender CM, Jones CK, Conn PJ, Daniels RN, Lindsley CW (2014) Bioorg Med Chem Lett 24(4): 1062-6
    › Primary publication · 24462664 (PubMed) · PMC3951244 (PubMed Central)
  92. Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: development of a potent and CNS penetrant [3.1.0]-based lead. Jones CK, Sheffler DJ, Williams R, Jadhav SB, Felts AS, Morrison RD, Niswender CM, Daniels JS, Conn PJ, Lindsley CW (2014) Bioorg Med Chem Lett 24(4): 1067-70
    › Primary publication · 24461352 (PubMed) · PMC3951249 (PubMed Central)
  93. Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100. Byun NE, Grannan M, Bubser M, Barry RL, Thompson A, Rosanelli J, Gowrishankar R, Kelm ND, Damon S, Bridges TM, Melancon BJ, Tarr JC, Brogan JT, Avison MJ, Deutch AY, Wess J, Wood MR, Lindsley CW, Gore JC, Conn PJ, Jones CK (2014) Neuropsychopharmacology 39(7): 1578-93
    › Primary publication · 24442096 (PubMed) · PMC4023154 (PubMed Central)
  94. Selective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNS. Yin S, Noetzel MJ, Johnson KA, Zamorano R, Jalan-Sakrikar N, Gregory KJ, Conn PJ, Niswender CM (2014) J Neurosci 34(1): 79-94
    › Primary publication · 24381270 (PubMed) · PMC3866496 (PubMed Central)
  95. Extracellular calcium modulates actions of orthosteric and allosteric ligands on metabotropic glutamate receptor 1α. Jiang JY, Nagaraju M, Meyer RC, Zhang L, Hamelberg D, Hall RA, Brown EM, Conn PJ, Yang JJ (2014) J Biol Chem 289(3): 1649-61
    › Primary publication · 24280223 (PubMed) · PMC3894344 (PubMed Central)
  96. Bringing together the academic drug discovery community. Slusher BS, Conn PJ, Frye S, Glicksman M, Arkin M (2013) Nat Rev Drug Discov 12(11): 811-2
    › Primary publication · 24172316 (PubMed) · PMC4076044 (PubMed Central)
  97. Discovery of the first M5-selective and CNS penetrant negative allosteric modulator (NAM) of a muscarinic acetylcholine receptor: (S)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one (ML375). Gentry PR, Kokubo M, Bridges TM, Kett NR, Harp JM, Cho HP, Smith E, Chase P, Hodder PS, Niswender CM, Daniels JS, Conn PJ, Wood MR, Lindsley CW (2013) J Med Chem 56(22): 9351-5
    › Primary publication · 24164599 (PubMed) · PMC3876027 (PubMed Central)
  98. Development of allosteric modulators of GPCRs for treatment of CNS disorders. Nickols HH, Conn PJ (2014) Neurobiol Dis : 55-71
    › Primary publication · 24076101 (PubMed) · PMC3875303 (PubMed Central)
  99. Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety. Felts AS, Rodriguez AL, Morrison RD, Venable DF, Manka JT, Bates BS, Blobaum AL, Byers FW, Daniels JS, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Emmitte KA (2013) Bioorg Med Chem Lett 23(21): 5779-85
    › Primary publication · 24074843 (PubMed) · PMC3846293 (PubMed Central)
  100. Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254). Turlington M, Noetzel MJ, Chun A, Zhou Y, Gogliotti RD, Nguyen ED, Gregory KJ, Vinson PN, Rook JM, Gogi KK, Xiang Z, Bridges TM, Daniels JS, Jones C, Niswender CM, Meiler J, Conn PJ, Lindsley CW, Stauffer SR (2013) J Med Chem 56(20): 7976-96
    › Primary publication · 24050755 (PubMed) · PMC3908770 (PubMed Central)
  101. Interview: interview with P Jeffrey Conn. Interview by Hannah Coaker. Conn PJ (2013) Future Med Chem 5(13): 1483-9
    › Primary publication · 24024942 (PubMed) · PMC4382960 (PubMed Central)
  102. Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments. Brundin P, Barker RA, Conn PJ, Dawson TM, Kieburtz K, Lees AJ, Schwarzschild MA, Tanner CM, Isaacs T, Duffen J, Matthews H, Wyse RK (2013) J Parkinsons Dis 3(3): 231-9
    › Primary publication · 24018336 (PubMed) · PMC4318242 (PubMed Central)
  103. Heterotropic activation of the midazolam hydroxylase activity of CYP3A by a positive allosteric modulator of mGlu5: in vitro to in vivo translation and potential impact on clinically relevant drug-drug interactions. Blobaum AL, Bridges TM, Byers FW, Turlington ML, Mattmann ME, Morrison RD, Mackie C, Lavreysen H, Bartolomé JM, Macdonald GJ, Steckler T, Jones CK, Niswender CM, Conn PJ, Lindsley CW, Stauffer SR, Daniels JS (2013) Drug Metab Dispos 41(12): 2066-75
    › Primary publication · 24003250 (PubMed) · PMC3834130 (PubMed Central)
  104. N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement. Gregory KJ, Herman EJ, Ramsey AJ, Hammond AS, Byun NE, Stauffer SR, Manka JT, Jadhav S, Bridges TM, Weaver CD, Niswender CM, Steckler T, Drinkenburg WH, Ahnaou A, Lavreysen H, Macdonald GJ, Bartolomé JM, Mackie C, Hrupka BJ, Caron MG, Daigle TL, Lindsley CW, Conn PJ, Jones CK (2013) J Pharmacol Exp Ther 347(2): 438-57
    › Primary publication · 23965381 (PubMed) · PMC3807069 (PubMed Central)
  105. Dihydrothiazolopyridone derivatives as a novel family of positive allosteric modulators of the metabotropic glutamate 5 (mGlu5) receptor. Bartolomé-Nebreda JM, Conde-Ceide S, Delgado F, Iturrino L, Pastor J, Pena MÁ, Trabanco AA, Tresadern G, Wassvik CM, Stauffer SR, Jadhav S, Gogi K, Vinson PN, Noetzel MJ, Days E, Weaver CD, Lindsley CW, Niswender CM, Jones CK, Conn PJ, Rombouts F, Lavreysen H, Macdonald GJ, Mackie C, Steckler T (2013) J Med Chem 56(18): 7243-59
    › Primary publication · 23947773 (PubMed) · PMC3924858 (PubMed Central)
  106. Octahydropyrrolo[3,4-c]pyrrole negative allosteric modulators of mGlu1. Manka JT, Rodriguez AL, Morrison RD, Venable DF, Cho HP, Blobaum AL, Daniels JS, Niswender CM, Conn PJ, Lindsley CW, Emmitte KA (2013) Bioorg Med Chem Lett 23(18): 5091-6
    › Primary publication · 23932792 (PubMed) · PMC3901432 (PubMed Central)
  107. Potentiating mGluR5 function with a positive allosteric modulator enhances adaptive learning. Xu J, Zhu Y, Kraniotis S, He Q, Marshall JJ, Nomura T, Stauffer SR, Lindsley CW, Conn PJ, Contractor A (2013) Learn Mem 20(8): 438-45
    › Primary publication · 23869026 (PubMed) · PMC3718201 (PubMed Central)
  108. Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizure-like adverse events in rats involving a receptor agonism-dependent mechanism. Bridges TM, Rook JM, Noetzel MJ, Morrison RD, Zhou Y, Gogliotti RD, Vinson PN, Xiang Z, Jones CK, Niswender CM, Lindsley CW, Stauffer SR, Conn PJ, Daniels JS (2013) Drug Metab Dispos 41(9): 1703-14
    › Primary publication · 23821185 (PubMed) · PMC3876804 (PubMed Central)
  109. N-Acyl-N'-arylpiperazines as negative allosteric modulators of mGlu1: identification of VU0469650, a potent and selective tool compound with CNS exposure in rats. Lovell KM, Felts AS, Rodriguez AL, Venable DF, Cho HP, Morrison RD, Byers FW, Daniels JS, Niswender CM, Conn PJ, Lindsley CW, Emmitte KA (2013) Bioorg Med Chem Lett 23(13): 3713-8
    › Primary publication · 23727046 (PubMed) · PMC3875306 (PubMed Central)
  110. Discovery of (R)-(2-fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-hydroxypiperidin-1-yl)methanone (ML337), an mGlu3 selective and CNS penetrant negative allosteric modulator (NAM). Wenthur CJ, Morrison R, Felts AS, Smith KA, Engers JL, Byers FW, Daniels JS, Emmitte KA, Conn PJ, Lindsley CW (2013) J Med Chem 56(12): 5208-12
    › Primary publication · 23718281 (PubMed) · PMC3769689 (PubMed Central)
  111. Substituted 1-Phenyl-3-(pyridin-2-yl)urea negative allosteric modulators of mGlu5: discovery of a new tool compound VU0463841 with activity in rat models of cocaine addiction. Amato RJ, Felts AS, Rodriguez AL, Venable DF, Morrison RD, Byers FW, Daniels JS, Niswender CM, Conn PJ, Lindsley CW, Jones CK, Emmitte KA (2013) ACS Chem Neurosci 4(8): 1217-28
    › Primary publication · 23682684 (PubMed) · PMC3750677 (PubMed Central)
  112. Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease. Dickerson JW, Conn PJ (2012) Neurodegener Dis Manag 2(2): 221-232
    › Primary publication · 23526920 (PubMed) · PMC3603000 (PubMed Central)
  113. Probing the metabotropic glutamate receptor 5 (mGlu₅) positive allosteric modulator (PAM) binding pocket: discovery of point mutations that engender a "molecular switch" in PAM pharmacology. Gregory KJ, Nguyen ED, Reiff SD, Squire EF, Stauffer SR, Lindsley CW, Meiler J, Conn PJ (2013) Mol Pharmacol 83(5): 991-1006
    › Primary publication · 23444015 (PubMed) · PMC3629835 (PubMed Central)
  114. Spirocyclic replacements for the isatin in the highly selective, muscarinic M1 PAM ML137: the continued optimization of an MLPCN probe molecule. Poslusney MS, Melancon BJ, Gentry PR, Sheffler DJ, Bridges TM, Utley TJ, Daniels JS, Niswender CM, Conn PJ, Lindsley CW, Wood MR (2013) Bioorg Med Chem Lett 23(6): 1860-4
    › Primary publication · 23416001 (PubMed) · PMC3594472 (PubMed Central)
  115. Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks. Menniti FS, Lindsley CW, Conn PJ, Pandit J, Zagouras P, Volkmann RA (2013) Curr Top Med Chem 13(1): 26-54
    › Primary publication · 23409764 (PubMed) · PMC3792577 (PubMed Central)
  116. A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling. Noetzel MJ, Gregory KJ, Vinson PN, Manka JT, Stauffer SR, Lindsley CW, Niswender CM, Xiang Z, Conn PJ (2013) Mol Pharmacol 83(4): 835-47
    › Primary publication · 23348500 (PubMed) · PMC3608436 (PubMed Central)
  117. Discovery of N-Aryl Piperazines as Selective mGlu(5) Potentiators with Efficacy in a Rodent Model Predictive of Anti-Psychotic Activity. Zhou Y, Manka JT, Rodriguez AL, Weaver CD, Days EL, Vinson PN, Jadhav S, Hermann EJ, Jones CK, Conn PJ, Lindsley CW, Stauffer SR (2010) ACS Med Chem Lett 1(8): 433-438
    › Primary publication · 23308336 (PubMed) · PMC3539763 (PubMed Central)
  118. Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling. Foster DJ, Jones CK, Conn PJ (2012) Discov Med 14(79): 413-20
    › Primary publication · 23272693 (PubMed) · PMC3726271 (PubMed Central)
  119. Chemical modification of the M(1) agonist VU0364572 reveals molecular switches in pharmacology and a bitopic binding mode. Digby GJ, Utley TJ, Lamsal A, Sevel C, Sheffler DJ, Lebois EP, Bridges TM, Wood MR, Niswender CM, Lindsley CW, Conn PJ (2012) ACS Chem Neurosci 3(12): 1025-36
    › Primary publication · 23259038 (PubMed) · PMC3526969 (PubMed Central)
  120. Isatin replacements applied to the highly selective, muscarinic M1 PAM ML137: continued optimization of an MLPCN probe molecule. Melancon BJ, Poslusney MS, Gentry PR, Tarr JC, Sheffler DJ, Mattmann ME, Bridges TM, Utley TJ, Daniels JS, Niswender CM, Conn PJ, Lindsley CW, Wood MR (2013) Bioorg Med Chem Lett 23(2): 412-6
    › Primary publication · 23237839 (PubMed) · PMC3534865 (PubMed Central)
  121. Further exploration of M₁ allosteric agonists: subtle structural changes abolish M₁ allosteric agonism and result in pan-mAChR orthosteric antagonism. Sheffler DJ, Sevel C, Le U, Lovell KM, Tarr JC, Carrington SJ, Cho HP, Digby GJ, Niswender CM, Conn PJ, Hopkins CR, Wood MR, Lindsley CW (2013) Bioorg Med Chem Lett 23(1): 223-7
    › Primary publication · 23200253 (PubMed) · PMC3525729 (PubMed Central)
  122. Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling. Noetzel MJ, Jones CK, Conn PJ (2012) Discov Med 14(78): 335-43
    › Primary publication · 23200065 (PubMed) · PMC3787874 (PubMed Central)
  123. Discovery of a selective M₄ positive allosteric modulator based on the 3-amino-thieno[2,3-b]pyridine-2-carboxamide scaffold: development of ML253, a potent and brain penetrant compound that is active in a preclinical model of schizophrenia. Le U, Melancon BJ, Bridges TM, Vinson PN, Utley TJ, Lamsal A, Rodriguez AL, Venable D, Sheffler DJ, Jones CK, Blobaum AL, Wood MR, Daniels JS, Conn PJ, Niswender CM, Lindsley CW, Hopkins CR (2013) Bioorg Med Chem Lett 23(1): 346-50
    › Primary publication · 23177787 (PubMed) · PMC3535830 (PubMed Central)
  124. Targeting selective activation of M(1) for the treatment of Alzheimer's disease: further chemical optimization and pharmacological characterization of the M(1) positive allosteric modulator ML169. Tarr JC, Turlington ML, Reid PR, Utley TJ, Sheffler DJ, Cho HP, Klar R, Pancani T, Klein MT, Bridges TM, Morrison RD, Blobaum AL, Xiang Z, Daniels JS, Niswender CM, Conn PJ, Wood MR, Lindsley CW (2012) ACS Chem Neurosci 3(11): 884-95
    › Primary publication · 23173069 (PubMed) · PMC3503349 (PubMed Central)
  125. Discovery and SAR of a novel series of non-MPEP site mGlu₅ PAMs based on an aryl glycine sulfonamide scaffold. Rodriguez AL, Zhou Y, Williams R, Weaver CD, Vinson PN, Dawson ES, Steckler T, Lavreysen H, Mackie C, Bartolomé JM, Macdonald GJ, Daniels JS, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Stauffer SR (2012) Bioorg Med Chem Lett 22(24): 7388-92
    › Primary publication · 23142615 (PubMed) · PMC3539767 (PubMed Central)
  126. Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity. Rook JM, Noetzel MJ, Pouliot WA, Bridges TM, Vinson PN, Cho HP, Zhou Y, Gogliotti RD, Manka JT, Gregory KJ, Stauffer SR, Dudek FE, Xiang Z, Niswender CM, Daniels JS, Jones CK, Lindsley CW, Conn PJ (2013) Biol Psychiatry 73(6): 501-9
    › Primary publication · 23140665 (PubMed) · PMC3572342 (PubMed Central)
  127. Synthesis and biological characterization of a series of novel diaryl amide M₁ antagonists. Poslusney MS, Sevel C, Utley TJ, Bridges TM, Morrison RD, Kett NR, Sheffler DJ, Niswender CM, Daniels JS, Conn PJ, Lindsley CW, Wood MR (2012) Bioorg Med Chem Lett 22(22): 6923-8
    › Primary publication · 23062550 (PubMed) · PMC3897205 (PubMed Central)
  128. Metabotropic glutamate receptors for new treatments in schizophrenia. Herman EJ, Bubser M, Conn PJ, Jones CK (2012) Handb Exp Pharmacol (213): 297-365
    › Primary publication · 23027420 (PubMed)
  129. Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence. Sidique S, Dhanya RP, Sheffler DJ, Nickols HH, Yang L, Dahl R, Mangravita-Novo A, Smith LH, D'Souza MS, Semenova S, Conn PJ, Markou A, Cosford ND (2012) J Med Chem 55(22): 9434-45
    › Primary publication · 23009245 (PubMed) · PMC3508153 (PubMed Central)
  130. Optimization of an ether series of mGlu5 positive allosteric modulators: molecular determinants of MPEP-site interaction crossover. Manka JT, Vinson PN, Gregory KJ, Zhou Y, Williams R, Gogi K, Days E, Jadhav S, Herman EJ, Lavreysen H, Mackie C, Bartolomé JM, Macdonald GJ, Steckler T, Daniels JS, Weaver CD, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Stauffer SR (2012) Bioorg Med Chem Lett 22(20): 6481-5
    › Primary publication · 22981332 (PubMed) · PMC3755010 (PubMed Central)
  131. Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships. Gregory KJ, Noetzel MJ, Rook JM, Vinson PN, Stauffer SR, Rodriguez AL, Emmitte KA, Zhou Y, Chun AC, Felts AS, Chauder BA, Lindsley CW, Niswender CM, Conn PJ (2012) Mol Pharmacol 82(5): 860-75
    › Primary publication · 22863693 (PubMed) · PMC3477233 (PubMed Central)
  132. Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012. Melancon BJ, Utley TJ, Sevel C, Mattmann ME, Cheung YY, Bridges TM, Morrison RD, Sheffler DJ, Niswender CM, Daniels JS, Conn PJ, Lindsley CW, Wood MR (2012) Bioorg Med Chem Lett 22(15): 5035-40
    › Primary publication · 22749871 (PubMed) · PMC3883446 (PubMed Central)
  133. Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptor. Salovich JM, Vinson PN, Sheffler DJ, Lamsal A, Utley TJ, Blobaum AL, Bridges TM, Le U, Jones CK, Wood MR, Daniels JS, Conn PJ, Niswender CM, Lindsley CW, Hopkins CR (2012) Bioorg Med Chem Lett 22(15): 5084-8
    › Primary publication · 22738637 (PubMed) · PMC3401285 (PubMed Central)
  134. Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models. Digby GJ, Noetzel MJ, Bubser M, Utley TJ, Walker AG, Byun NE, Lebois EP, Xiang Z, Sheffler DJ, Cho HP, Davis AA, Nemirovsky NE, Mennenga SE, Camp BW, Bimonte-Nelson HA, Bode J, Italiano K, Morrison R, Daniels JS, Niswender CM, Olive MF, Lindsley CW, Jones CK, Conn PJ (2012) J Neurosci 32(25): 8532-44
    › Primary publication · 22723693 (PubMed) · PMC3398407 (PubMed Central)
  135. The role of aldehyde oxidase and xanthine oxidase in the biotransformation of a novel negative allosteric modulator of metabotropic glutamate receptor subtype 5. Morrison RD, Blobaum AL, Byers FW, Santomango TS, Bridges TM, Stec D, Brewer KA, Sanchez-Ponce R, Corlew MM, Rush R, Felts AS, Manka J, Bates BS, Venable DF, Rodriguez AL, Jones CK, Niswender CM, Conn PJ, Lindsley CW, Emmitte KA, Daniels JS (2012) Drug Metab Dispos 40(9): 1834-45
    › Primary publication · 22711749 (PubMed) · PMC3422546 (PubMed Central)
  136. Potentiation of mGlu5 receptors with the novel enhancer, VU0360172, reduces spontaneous absence seizures in WAG/Rij rats. D'Amore V, Santolini I, van Rijn CM, Biagioni F, Molinaro G, Prete A, Conn PJ, Lindsley CW, Zhou Y, Vinson PN, Rodriguez AL, Jones CK, Stauffer SR, Nicoletti F, van Luijtelaar G, Ngomba RT (2013) Neuropharmacology : 330-8
    › Primary publication · 22705340 (PubMed) · PMC3787880 (PubMed Central)
  137. Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM. Sheffler DJ, Wenthur CJ, Bruner JA, Carrington SJ, Vinson PN, Gogi KK, Blobaum AL, Morrison RD, Vamos M, Cosford ND, Stauffer SR, Daniels JS, Niswender CM, Conn PJ, Lindsley CW (2012) Bioorg Med Chem Lett 22(12): 3921-5
    › Primary publication · 22607673 (PubMed) · PMC3365510 (PubMed Central)
  138. Iterative experimental and virtual high-throughput screening identifies metabotropic glutamate receptor subtype 4 positive allosteric modulators. Mueller R, Dawson ES, Niswender CM, Butkiewicz M, Hopkins CR, Weaver CD, Lindsley CW, Conn PJ, Meiler J (2012) J Mol Model 18(9): 4437-46
    › Primary publication · 22592386 (PubMed) · PMC3766737 (PubMed Central)
  139. The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease. Johnson KA, Jones CK, Tantawy MN, Bubser M, Marvanova M, Ansari MS, Baldwin RM, Conn PJ, Niswender CM (2013) Neuropharmacology : 187-95
    › Primary publication · 22546615 (PubMed) · PMC3432150 (PubMed Central)
  140. Modulation of pyramidal cell output in the medial prefrontal cortex by mGluR5 interacting with CB1. Kiritoshi T, Sun H, Ren W, Stauffer SR, Lindsley CW, Conn PJ, Neugebauer V (2013) Neuropharmacology : 170-8
    › Primary publication · 22521499 (PubMed) · PMC3568505 (PubMed Central)
  141. Continued optimization of the MLPCN probe ML071 into highly potent agonists of the hM1 muscarinic acetylcholine receptor. Melancon BJ, Gogliotti RD, Tarr JC, Saleh SA, Chauder BA, Lebois EP, Cho HP, Utley TJ, Sheffler DJ, Bridges TM, Morrison RD, Daniels JS, Niswender CM, Conn PJ, Lindsley CW, Wood MR (2012) Bioorg Med Chem Lett 22(10): 3467-72
    › Primary publication · 22507963 (PubMed) · PMC3348459 (PubMed Central)
  142. An interview with P. Jeffrey Conn. Conn PJ (2012) Trends Pharmacol Sci 33(3): 119-21
    › Primary publication · 22489320 (PubMed)
  143. Functional selectivity induced by mGlu₄ receptor positive allosteric modulation and concomitant activation of Gq coupled receptors. Yin S, Zamorano R, Conn PJ, Niswender CM (2013) Neuropharmacology : 122-32
    › Primary publication · 22426233 (PubMed) · PMC3412075 (PubMed Central)
  144. The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. Xiang Z, Thompson AD, Brogan JT, Schulte ML, Melancon BJ, Mi D, Lewis LM, Zou B, Yang L, Morrison R, Santomango T, Byers F, Brewer K, Aldrich JS, Yu H, Dawson ES, Li M, McManus O, Jones CK, Daniels JS, Hopkins CR, Xie XS, Conn PJ, Weaver CD, Lindsley CW (2011) ACS Chem Neurosci 2(12): 730-742
    › Primary publication · 22368764 (PubMed) · PMC3285241 (PubMed Central)
  145. Discovery of 2-(2-benzoxazoyl amino)-4-aryl-5-cyanopyrimidine as negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGlu₅): from an artificial neural network virtual screen to an in vivo tool compound. Mueller R, Dawson ES, Meiler J, Rodriguez AL, Chauder BA, Bates BS, Felts AS, Lamb JP, Menon UN, Jadhav SB, Kane AS, Jones CK, Gregory KJ, Niswender CM, Conn PJ, Olsen CM, Winder DG, Emmitte KA, Lindsley CW (2012) ChemMedChem 7(3): 406-14
    › Primary publication · 22267125 (PubMed) · PMC3517057 (PubMed Central)
  146. Development of a more highly selective M(1) antagonist from the continued optimization of the MLPCN Probe ML012. Melancon BJ, Lamers AP, Bridges TM, Sulikowski GA, Utley TJ, Sheffler DJ, Noetzel MJ, Morrison RD, Daniels JS, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Wood MR (2012) Bioorg Med Chem Lett 22(2): 1044-8
    › Primary publication · 22197142 (PubMed) · PMC3434972 (PubMed Central)
  147. Neurotherapeutics. Smith GS, Li X, Conn PJ (2012) Neuropsychopharmacology 37(1): 1-3
    › Primary publication · 22157854 (PubMed) · PMC3238089 (PubMed Central)
  148. Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. Melancon BJ, Hopkins CR, Wood MR, Emmitte KA, Niswender CM, Christopoulos A, Conn PJ, Lindsley CW (2012) J Med Chem 55(4): 1445-64
    › Primary publication · 22148748 (PubMed) · PMC3349997 (PubMed Central)
  149. Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease. Xiang Z, Thompson AD, Jones CK, Lindsley CW, Conn PJ (2012) J Pharmacol Exp Ther 340(3): 595-603
    › Primary publication · 22135383 (PubMed) · PMC3286317 (PubMed Central)
  150. MAOS ls for the general synthesis and lead optimization of 3,6-disubstituted-[1,2,4]triazolo[4,3-b]pyridazines. Aldrich LN, Lebois EP, Lewis LM, Nalywajko NT, Niswender CM, Weaver CD, Conn PJ, Lindsley CW (2009) Tetrahedron Lett 50(2): 212-215
    › Primary publication · 22090663 (PubMed) · PMC3214729 (PubMed Central)
  151. The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. Jones CK, Bubser M, Thompson AD, Dickerson JW, Turle-Lorenzo N, Amalric M, Blobaum AL, Bridges TM, Morrison RD, Jadhav S, Engers DW, Italiano K, Bode J, Daniels JS, Lindsley CW, Hopkins CR, Conn PJ, Niswender CM (2012) J Pharmacol Exp Ther 340(2): 404-21
    › Primary publication · 22088953 (PubMed) · PMC3263969 (PubMed Central)
  152. Advancing drug discovery for schizophrenia. Marder SR, Roth B, Sullivan PF, Scolnick EM, Nestler EJ, Geyer MA, Welnberger DR, Karayiorgou M, Guidotti A, Gingrich J, Akbarian S, Buchanan RW, Lieberman JA, Conn PJ, Haggarty SJ, Law AJ, Campbell B, Krystal JH, Moghaddam B, Sawa A, Saw A, Caron MG, George SR, Allen JA, Solis M (2011) Ann N Y Acad Sci : 30-43
    › Primary publication · 22032400 (PubMed) · PMC3787879 (PubMed Central)
  153. Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function. Noetzel MJ, Rook JM, Vinson PN, Cho HP, Days E, Zhou Y, Rodriguez AL, Lavreysen H, Stauffer SR, Niswender CM, Xiang Z, Daniels JS, Jones CK, Lindsley CW, Weaver CD, Conn PJ (2012) Mol Pharmacol 81(2): 120-33
    › Primary publication · 22021324 (PubMed) · PMC3263948 (PubMed Central)
  154. Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model. Jones CK, Engers DW, Thompson AD, Field JR, Blobaum AL, Lindsley SR, Zhou Y, Gogliotti RD, Jadhav S, Zamorano R, Bogenpohl J, Smith Y, Morrison R, Daniels JS, Weaver CD, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR (2011) J Med Chem 54(21): 7639-47
    › Primary publication · 21966889 (PubMed) · PMC3226828 (PubMed Central)
  155. Contribution of both M1 and M4 receptors to muscarinic agonist-mediated attenuation of the cocaine discriminative stimulus in mice. Thomsen M, Lindsley CW, Conn PJ, Wessell JE, Fulton BS, Wess J, Caine SB (2012) Psychopharmacology (Berl) 220(4): 673-85
    › Primary publication · 21964721 (PubMed) · PMC3314162 (PubMed Central)
  156. Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system. Lebois EP, Bridges TM, Lewis LM, Dawson ES, Kane AS, Xiang Z, Jadhav SB, Yin H, Kennedy JP, Meiler J, Niswender CM, Jones CK, Conn PJ, Weaver CD, Lindsley CW (2010) ACS Chem Neurosci 1(2): 104-121
    › Primary publication · 21961051 (PubMed) · PMC3180826 (PubMed Central)
  157. Targeting glutamate synapses in schizophrenia. Field JR, Walker AG, Conn PJ (2011) Trends Mol Med 17(12): 689-98
    › Primary publication · 21955406 (PubMed) · PMC3225651 (PubMed Central)
  158. Activation of group II metabotropic glutamate receptors induces long-term depression of excitatory synaptic transmission in the substantia nigra pars reticulata. Johnson KA, Niswender CM, Conn PJ, Xiang Z (2011) Neurosci Lett 504(2): 102-106
    › Primary publication · 21945652 (PubMed) · PMC3556513 (PubMed Central)
  159. Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071. Lebois EP, Digby GJ, Sheffler DJ, Melancon BJ, Tarr JC, Cho HP, Miller NR, Morrison R, Bridges TM, Xiang Z, Daniels JS, Wood MR, Conn PJ, Lindsley CW (2011) Bioorg Med Chem Lett 21(21): 6451-5
    › Primary publication · 21930376 (PubMed) · PMC3190051 (PubMed Central)
  160. (3-Cyano-5-fluorophenyl)biaryl negative allosteric modulators of mGlu(5): Discovery of a new tool compound with activity in the OSS mouse model of addiction. Lindsley CW, Bates BS, Menon UN, Jadhav SB, Kane AS, Jones CK, Rodriguez AL, Conn PJ, Olsen CM, Winder DG, Emmitte KA (2011) ACS Chem Neurosci 2(8): 471-482
    › Primary publication · 21927650 (PubMed) · PMC3172161 (PubMed Central)
  161. Allosteric modulation of metabotropic glutamate receptors. Sheffler DJ, Gregory KJ, Rook JM, Conn PJ (2011) Adv Pharmacol : 37-77
    › Primary publication · 21907906 (PubMed) · PMC3787868 (PubMed Central)
  162. Metabotropic glutamate receptors as therapeutic targets for schizophrenia. Vinson PN, Conn PJ (2012) Neuropharmacology 62(3): 1461-72
    › Primary publication · 21620876 (PubMed) · PMC3189289 (PubMed Central)
  163. Impact of isoflurane anesthesia on D2 receptor occupancy by [18F]fallypride measured by microPET with a modified Logan plot. Tantawy MN, Peterson TE, Jones CK, Johnson K, Rook JM, Conn PJ, Baldwin RM, Ansari MS, Kessler RM (2011) Synapse 65(11): 1173-80
    › Primary publication · 21584868 (PubMed) · PMC4078917 (PubMed Central)
  164. Potent mGluR5 antagonists: pyridyl and thiazolyl-ethynyl-3,5-disubstituted-phenyl series. Alagille D, DaCosta H, Chen Y, Hemstapat K, Rodriguez A, Baldwin RM, Conn PJ, Conn JP, Tamagnan GD (2011) Bioorg Med Chem Lett 21(11): 3243-7
    › Primary publication · 21546249 (PubMed) · PMC3826776 (PubMed Central)
  165. "Molecular switches" on mGluR allosteric ligands that modulate modes of pharmacology. Wood MR, Hopkins CR, Brogan JT, Conn PJ, Lindsley CW (2011) Biochemistry 50(13): 2403-10
    › Primary publication · 21341760 (PubMed) · PMC3792571 (PubMed Central)
  166. Solution-phase parallel synthesis and SAR of homopiperazinyl analogs as positive allosteric modulators of mGlu₄. Cheung YY, Zamorano R, Blobaum AL, Weaver CD, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR (2011) ACS Comb Sci 13(2): 159-65
    › Primary publication · 21338051 (PubMed) · PMC3057427 (PubMed Central)
  167. Synthesis and SAR of centrally active mGlu5 positive allosteric modulators based on an aryl acetylenic bicyclic lactam scaffold. Williams R, Manka JT, Rodriguez AL, Vinson PN, Niswender CM, Weaver CD, Jones CK, Conn PJ, Lindsley CW, Stauffer SR (2011) Bioorg Med Chem Lett 21(5): 1350-3
    › Primary publication · 21315585 (PubMed) · PMC3498823 (PubMed Central)
  168. Design and synthesis of substituted N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides as positive allosteric modulators of the metabotropic glutamate receptor subtype 5. Zou MF, Cao J, Rodriguez AL, Conn PJ, Newman AH (2011) Bioorg Med Chem Lett 21(9): 2650-4
    › Primary publication · 21295978 (PubMed) · PMC3081927 (PubMed Central)
  169. Discovery, synthesis, and structure-activity relationship development of a series of N-(4-acetamido)phenylpicolinamides as positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu(4)) with CNS exposure in rats. Engers DW, Field JR, Le U, Zhou Y, Bolinger JD, Zamorano R, Blobaum AL, Jones CK, Jadhav S, Weaver CD, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR (2011) J Med Chem 54(4): 1106-10
    › Primary publication · 21247167 (PubMed) · PMC3166797 (PubMed Central)
  170. Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probe. Reid PR, Bridges TM, Sheffler DJ, Cho HP, Lewis LM, Days E, Daniels JS, Jones CK, Niswender CM, Weaver CD, Conn PJ, Lindsley CW, Wood MR (2011) Bioorg Med Chem Lett 21(9): 2697-701
    › Primary publication · 21194936 (PubMed) · PMC3082000 (PubMed Central)
  171. Discovery of molecular switches within the ADX-47273 mGlu5 PAM scaffold that modulate modes of pharmacology to afford potent mGlu5 NAMs, PAMs and partial antagonists. Lamb JP, Engers DW, Niswender CM, Rodriguez AL, Venable DF, Conn PJ, Lindsley CW (2011) Bioorg Med Chem Lett 21(9): 2711-4
    › Primary publication · 21183344 (PubMed) · PMC3179182 (PubMed Central)
  172. Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats. Dhanya RP, Sidique S, Sheffler DJ, Nickols HH, Herath A, Yang L, Dahl R, Ardecky R, Semenova S, Markou A, Conn PJ, Cosford ND (2011) J Med Chem 54(1): 342-53
    › Primary publication · 21155570 (PubMed) · PMC3071440 (PubMed Central)
  173. Metabotropic glutamate receptors: from the workbench to the bedside. Nicoletti F, Bockaert J, Collingridge GL, Conn PJ, Ferraguti F, Schoepp DD, Wroblewski JT, Pin JP (2011) Neuropharmacology 60(7-8): 1017-41
    › Primary publication · 21036182 (PubMed) · PMC3787883 (PubMed Central)
  174. Discovery of a Novel Chemical Class of mGlu(5) Allosteric Ligands with Distinct Modes of Pharmacology. Hammond AS, Rodriguez AL, Townsend SD, Niswender CM, Gregory KJ, Lindsley CW, Conn PJ (2010) ACS Chem Neurosci 1(10): 702-716
    › Primary publication · 20981342 (PubMed) · PMC2957851 (PubMed Central)
  175. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Rodriguez AL, Grier MD, Jones CK, Herman EJ, Kane AS, Smith RL, Williams R, Zhou Y, Marlo JE, Days EL, Blatt TN, Jadhav S, Menon UN, Vinson PN, Rook JM, Stauffer SR, Niswender CM, Lindsley CW, Weaver CD, Conn PJ (2010) Mol Pharmacol 78(6): 1105-23
    › Primary publication · 20923853 (PubMed) · PMC2993468 (PubMed Central)
  176. Differential effects of allosteric M(1) muscarinic acetylcholine receptor agonists on receptor activation, arrestin 3 recruitment, and receptor downregulation. Davis AA, Heilman CJ, Brady AE, Miller NR, Fuerstenau-Sharp M, Hanson BJ, Lindsley CW, Conn PJ, Lah JJ, Levey AI (2010) ACS Chem Neurosci 1(8): 542-551
    › Primary publication · 20835371 (PubMed) · PMC2936488 (PubMed Central)
  177. Orthosteric- and allosteric-induced ligand-directed trafficking at GPCRs. Digby GJ, Conn PJ, Lindsley CW (2010) Curr Opin Drug Discov Devel 13(5): 587-94
    › Primary publication · 20812150 (PubMed) · PMC3821179 (PubMed Central)
  178. Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators. Bridges TM, Kennedy JP, Hopkins CR, Conn PJ, Lindsley CW (2010) Bioorg Med Chem Lett 20(19): 5617-22
    › Primary publication · 20801651 (PubMed) · PMC3179183 (PubMed Central)
  179. 3D-QSAR CoMFA study of benzoxazepine derivatives as mGluR5 positive allosteric modulators. Lowe EW, Ferrebee A, Rodriguez AL, Conn PJ, Meiler J (2010) Bioorg Med Chem Lett 20(19): 5922-4
    › Primary publication · 20732812 (PubMed) · PMC2943337 (PubMed Central)
  180. Synthesis and SAR of novel, 4-(phenylsulfamoyl)phenylacetamide mGlu4 positive allosteric modulators (PAMs) identified by functional high-throughput screening (HTS). Engers DW, Gentry PR, Williams R, Bolinger JD, Weaver CD, Menon UN, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR (2010) Bioorg Med Chem Lett 20(17): 5175-8
    › Primary publication · 20667732 (PubMed) · PMC2922490 (PubMed Central)
  181. Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential. Gregory KJ, Dong EN, Meiler J, Conn PJ (2011) Neuropharmacology 60(1): 66-81
    › Primary publication · 20637216 (PubMed) · PMC2981682 (PubMed Central)
  182. 3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure in rats. Felts AS, Lindsley SR, Lamb JP, Rodriguez AL, Menon UN, Jadhav S, Jones CK, Conn PJ, Lindsley CW, Emmitte KA (2010) Bioorg Med Chem Lett 20(15): 4390-4
    › Primary publication · 20598884 (PubMed) · PMC2905502 (PubMed Central)
  183. Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders. Digby GJ, Shirey JK, Conn PJ (2010) Mol Biosyst 6(8): 1345-54
    › Primary publication · 20582339 (PubMed) · PMC4780333 (PubMed Central)
  184. Re-exploration of the PHCCC Scaffold: Discovery of Improved Positive Allosteric Modulators of mGluR4. Williams R, Zhou Y, Niswender CM, Luo Q, Conn PJ, Lindsley CW, Hopkins CR (2010) ACS Chem Neurosci 1(6): 411-419
    › Primary publication · 20582156 (PubMed) · PMC2889702 (PubMed Central)
  185. The mGluR2 positive allosteric modulator BINA decreases cocaine self-administration and cue-induced cocaine-seeking and counteracts cocaine-induced enhancement of brain reward function in rats. Jin X, Semenova S, Yang L, Ardecky R, Sheffler DJ, Dahl R, Conn PJ, Cosford ND, Markou A (2010) Neuropsychopharmacology 35(10): 2021-36
    › Primary publication · 20555310 (PubMed) · PMC2922422 (PubMed Central)
  186. The antipsychotic potential of muscarinic allosteric modulation. Bridges TM, LeBois EP, Hopkins CR, Wood MR, Jones CK, Conn PJ, Lindsley CW (2010) Drug News Perspect 23(4): 229-40
    › Primary publication · 20520852 (PubMed) · PMC4780339 (PubMed Central)
  187. Identification of Metabotropic Glutamate Receptor Subtype 5 Potentiators Using Virtual High-Throughput Screening. Mueller R, Rodriguez AL, Dawson ES, Butkiewicz M, Nguyen TT, Oleszkiewicz S, Bleckmann A, Weaver CD, Lindsley CW, Conn PJ, Meiler J (2010) ACS Chem Neurosci 1(4): 288-305
    › Primary publication · 20414370 (PubMed) · PMC2857954 (PubMed Central)
  188. Structure-activity relationships in a novel series of 7-substituted-aryl quinolines and 5-substituted-aryl benzothiazoles at the metabotropic glutamate receptor subtype 5. Zhang P, Zou MF, Rodriguez AL, Conn PJ, Newman AH (2010) Bioorg Med Chem 18(9): 3026-35
    › Primary publication · 20382541 (PubMed) · PMC2871681 (PubMed Central)
  189. Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation. Hackler EA, Byun NE, Jones CK, Williams JM, Baheza R, Sengupta S, Grier MD, Avison M, Conn PJ, Gore JC (2010) Neuroscience 168(1): 209-18
    › Primary publication · 20350588 (PubMed) · PMC3598608 (PubMed Central)
  190. Synthesis and SAR of N-(4-(4-alklylpiperazin-1-yl)phenyl)benzamides as muscarinic acetylcholine receptor subtype 1 (M1) anatgonists. Miller NR, Daniels RN, Lee D, Conn PJ, Lindsley CW (2010) Bioorg Med Chem Lett 20(7): 2174-7
    › Primary publication · 20202841 (PubMed) · PMC2843780 (PubMed Central)
  191. Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part II: development of a potent and highly selective M1 PAM. Bridges TM, Phillip Kennedy J, Noetzel MJ, Breininger ML, Gentry PR, Conn PJ, Lindsley CW (2010) Bioorg Med Chem Lett 20(6): 1972-5
    › Primary publication · 20156687 (PubMed) · PMC2834874 (PubMed Central)
  192. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Niswender CM, Conn PJ (2010) Annu Rev Pharmacol Toxicol : 295-322
    › Primary publication · 20055706 (PubMed) · PMC2904507 (PubMed Central)
  193. Context-dependent pharmacology exhibited by negative allosteric modulators of metabotropic glutamate receptor 7. Niswender CM, Johnson KA, Miller NR, Ayala JE, Luo Q, Williams R, Saleh S, Orton D, Weaver CD, Conn PJ (2010) Mol Pharmacol 77(3): 459-68
    › Primary publication · 20026717 (PubMed) · PMC2835423 (PubMed Central)
  194. Chemical lead optimization of a pan G(q) mAChR M(1), M(3), M(5) positive allosteric modulator (PAM) lead. Part I: Development of the first highly selective M(5) PAM. Bridges TM, Kennedy JP, Cho HP, Breininger ML, Gentry PR, Hopkins CR, Conn PJ, Lindsley CW (2010) Bioorg Med Chem Lett 20(2): 558-62
    › Primary publication · 20004578 (PubMed) · PMC3177601 (PubMed Central)
  195. Attenuation of cocaine's reinforcing and discriminative stimulus effects via muscarinic M1 acetylcholine receptor stimulation. Thomsen M, Conn PJ, Lindsley C, Wess J, Boon JY, Fulton BS, Fink-Jensen A, Caine SB (2010) J Pharmacol Exp Ther 332(3): 959-69
    › Primary publication · 19996296 (PubMed) · PMC2835434 (PubMed Central)
  196. A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. Shirey JK, Brady AE, Jones PJ, Davis AA, Bridges TM, Kennedy JP, Jadhav SB, Menon UN, Xiang Z, Watson ML, Christian EP, Doherty JJ, Quirk MC, Snyder DH, Lah JJ, Levey AI, Nicolle MM, Lindsley CW, Conn PJ (2009) J Neurosci 29(45): 14271-86
    › Primary publication · 19906975 (PubMed) · PMC2811323 (PubMed Central)
  197. Synthesis and SAR of novel, non-MPEP chemotype mGluR5 NAMs identified by functional HTS. Zhou Y, Rodriguez AL, Williams R, Weaver CD, Conn PJ, Lindsley CW (2009) Bioorg Med Chem Lett 19(23): 6502-6
    › Primary publication · 19875287 (PubMed) · PMC3177597 (PubMed Central)
  198. [(18)F]Fallypride dopamine D2 receptor studies using delayed microPET scans and a modified Logan plot. Tantawy MN, Jones CK, Baldwin RM, Ansari MS, Conn PJ, Kessler RM, Peterson TE (2009) Nucl Med Biol 36(8): 931-40
    › Primary publication · 19875049 (PubMed) · PMC2771119 (PubMed Central)
  199. Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Felts AS, Saleh SA, Le U, Rodriguez AL, Weaver CD, Conn PJ, Lindsley CW, Emmitte KA (2009) Bioorg Med Chem Lett 19(23): 6623-6
    › Primary publication · 19854049 (PubMed) · PMC2801349 (PubMed Central)
  200. Discovery and development of a potent and highly selective small molecule muscarinic acetylcholine receptor subtype I (mAChR 1 or M1) antagonist in vitro and in vivo probe. Weaver CD, Sheffler DJ, Lewis LM, Bridges TM, Williams R, Nalywajko NT, Kennedy JP, Mulder MM, Jadhav S, Aldrich LA, Jones CK, Marlo JE, Niswender CM, Mock MM, Zheng F, Conn PJ, Lindsley CW (2009) Curr Top Med Chem 9(13): 1217-26
    › Primary publication · 19807667 (PubMed) · PMC4765323 (PubMed Central)
  201. Synthesis and structure-activity relationships of allosteric potentiators of the m(4) muscarinic acetylcholine receptor. Kennedy JP, Bridges TM, Gentry PR, Brogan JT, Kane AS, Jones CK, Brady AE, Shirey JK, Conn PJ, Lindsley CW (2009) ChemMedChem 4(10): 1600-7
    › Primary publication · 19705385 (PubMed) · PMC2887613 (PubMed Central)
  202. Glutamate receptors as therapeutic targets for Parkinson's disease. Johnson KA, Conn PJ, Niswender CM (2009) CNS Neurol Disord Drug Targets 8(6): 475-91
    › Primary publication · 19702565 (PubMed) · PMC3005251 (PubMed Central)
  203. Synthesis and SAR of a novel positive allosteric modulator (PAM) of the metabotropic glutamate receptor 4 (mGluR4). Williams R, Johnson KA, Gentry PR, Niswender CM, Weaver CD, Conn PJ, Lindsley CW, Hopkins CR (2009) Bioorg Med Chem Lett 19(17): 4967-70
    › Primary publication · 19640716 (PubMed) · PMC2752865 (PubMed Central)
  204. Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a series of functionalized, regioisomeric 2- and 5-(phenylethynyl)pyrimidines. Sharma S, Kedrowski J, Rook JM, Smith RL, Jones CK, Rodriguez AL, Conn PJ, Lindsley CW (2009) J Med Chem 52(14): 4103-6
    › Primary publication · 19537763 (PubMed) · PMC3192011 (PubMed Central)
  205. Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs). Engers DW, Niswender CM, Weaver CD, Jadhav S, Menon UN, Zamorano R, Conn PJ, Lindsley CW, Hopkins CR (2009) J Med Chem 52(14): 4115-8
    › Primary publication · 19469556 (PubMed) · PMC2765192 (PubMed Central)
  206. Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substituted-arylethynyl)thiazoles as novel metabotropic glutamate receptor subtype 5 antagonists. Kulkarni SS, Zou MF, Cao J, Deschamps JR, Rodriguez AL, Conn PJ, Newman AH (2009) J Med Chem 52(11): 3563-75
    › Primary publication · 19445453 (PubMed) · PMC2894482 (PubMed Central)
  207. Discovery and SAR of novel mGluR5 non-competitive antagonists not based on an MPEP chemotype. Rodriguez AL, Williams R, Zhou Y, Lindsley SR, Le U, Grier MD, Weaver CD, Conn PJ, Lindsley CW (2009) Bioorg Med Chem Lett 19(12): 3209-13
    › Primary publication · 19443219 (PubMed) · PMC3177605 (PubMed Central)
  208. A novel class of H3 antagonists derived from the natural product guided synthesis of unnatural analogs of the marine bromopyrrole alkaloid dispyrin. Kennedy JP, Conn PJ, Lindsley CW (2009) Bioorg Med Chem Lett 19(12): 3204-8
    › Primary publication · 19443215 (PubMed) · PMC4793969 (PubMed Central)
  209. Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins. Bridges TM, Marlo JE, Niswender CM, Jones CK, Jadhav SB, Gentry PR, Plumley HC, Weaver CD, Conn PJ, Lindsley CW (2009) J Med Chem 52(11): 3445-8
    › Primary publication · 19438238 (PubMed) · PMC3875304 (PubMed Central)
  210. A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning. Sheffler DJ, Williams R, Bridges TM, Xiang Z, Kane AS, Byun NE, Jadhav S, Mock MM, Zheng F, Lewis LM, Jones CK, Niswender CM, Weaver CD, Lindsley CW, Conn PJ (2009) Mol Pharmacol 76(2): 356-68
    › Primary publication · 19407080 (PubMed) · PMC2713127 (PubMed Central)
  211. mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning. Ayala JE, Chen Y, Banko JL, Sheffler DJ, Williams R, Telk AN, Watson NL, Xiang Z, Zhang Y, Jones PJ, Lindsley CW, Olive MF, Conn PJ (2009) Neuropsychopharmacology 34(9): 2057-71
    › Primary publication · 19295507 (PubMed) · PMC2884290 (PubMed Central)
  212. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Conn PJ, Jones CK, Lindsley CW (2009) Trends Pharmacol Sci 30(3): 148-55
    › Primary publication · 19201489 (PubMed) · PMC2907736 (PubMed Central)
  213. Synthesis, SAR and unanticipated pharmacological profiles of analogues of the mGluR5 ago-potentiator ADX-47273. Engers DW, Rodriguez AL, Williams R, Hammond AS, Venable D, Oluwatola O, Sulikowski GA, Conn PJ, Lindsley CW (2009) ChemMedChem 4(4): 505-11
    › Primary publication · 19197923 (PubMed) · PMC2865690 (PubMed Central)
  214. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Conn PJ, Christopoulos A, Lindsley CW (2009) Nat Rev Drug Discov 8(1): 41-54
    › Primary publication · 19116626 (PubMed) · PMC2907734 (PubMed Central)
  215. Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4). Part II: Challenges in hit-to-lead. Williams R, Niswender CM, Luo Q, Le U, Conn PJ, Lindsley CW (2009) Bioorg Med Chem Lett 19(3): 962-6
    › Primary publication · 19097893 (PubMed) · PMC3787871 (PubMed Central)
  216. Promise of mGluR2/3 activators in psychiatry. Conn PJ, Jones CK (2009) Neuropsychopharmacology 34(1): 248-9
    › Primary publication · 19079073 (PubMed) · PMC2907744 (PubMed Central)
  217. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Conn PJ, Lindsley CW, Jones CK (2009) Trends Pharmacol Sci 30(1): 25-31
    › Primary publication · 19058862 (PubMed) · PMC2907735 (PubMed Central)
  218. Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Marlo JE, Niswender CM, Days EL, Bridges TM, Xiang Y, Rodriguez AL, Shirey JK, Brady AE, Nalywajko T, Luo Q, Austin CA, Williams MB, Kim K, Williams R, Orton D, Brown HA, Lindsley CW, Weaver CD, Conn PJ (2009) Mol Pharmacol 75(3): 577-88
    › Primary publication · 19047481 (PubMed) · PMC2684909 (PubMed Central)
  219. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN, Kane AS, Bridges TM, Kennedy JP, Bradley SR, Peterson TE, Ansari MS, Baldwin RM, Kessler RM, Deutch AY, Lah JJ, Levey AI, Lindsley CW, Conn PJ (2008) J Neurosci 28(41): 10422-33
    › Primary publication · 18842902 (PubMed) · PMC2577155 (PubMed Central)
  220. Synthesis and SAR of analogs of the M1 allosteric agonist TBPB. Part II: Amides, sulfonamides and ureas--the effect of capping the distal basic piperidine nitrogen. Miller NR, Daniels RN, Bridges TM, Brady AE, Conn PJ, Lindsley CW (2008) Bioorg Med Chem Lett 18(20): 5443-7
    › Primary publication · 18829311 (PubMed) · PMC3177607 (PubMed Central)
  221. Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl and privileged structure moieties. Bridges TM, Brady AE, Kennedy JP, Daniels RN, Miller NR, Kim K, Breininger ML, Gentry PR, Brogan JT, Jones CK, Conn PJ, Lindsley CW (2008) Bioorg Med Chem Lett 18(20): 5439-42
    › Primary publication · 18805692 (PubMed) · PMC3177598 (PubMed Central)
  222. Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4): Part I. Discovery of pyrazolo[3,4-d]pyrimidines as novel mGluR4 positive allosteric modulators. Niswender CM, Lebois EP, Luo Q, Kim K, Muchalski H, Yin H, Conn PJ, Lindsley CW (2008) Bioorg Med Chem Lett 18(20): 5626-30
    › Primary publication · 18793851 (PubMed) · PMC3182458 (PubMed Central)
  223. Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. Brady AE, Jones CK, Bridges TM, Kennedy JP, Thompson AD, Heiman JU, Breininger ML, Gentry PR, Yin H, Jadhav SB, Shirey JK, Conn PJ, Lindsley CW (2008) J Pharmacol Exp Ther 327(3): 941-53
    › Primary publication · 18772318 (PubMed) · PMC2745822 (PubMed Central)
  224. Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Niswender CM, Johnson KA, Weaver CD, Jones CK, Xiang Z, Luo Q, Rodriguez AL, Marlo JE, de Paulis T, Thompson AD, Days EL, Nalywajko T, Austin CA, Williams MB, Ayala JE, Williams R, Lindsley CW, Conn PJ (2008) Mol Pharmacol 74(5): 1345-58
    › Primary publication · 18664603 (PubMed) · PMC2574552 (PubMed Central)
  225. Allosteric potentiators of metabotropic glutamate receptor subtype 1a differentially modulate independent signaling pathways in baby hamster kidney cells. Sheffler DJ, Conn PJ (2008) Neuropharmacology 55(4): 419-27
    › Primary publication · 18625258 (PubMed) · PMC2600811 (PubMed Central)
  226. Metabotropic glutamate receptors mGluR4 and mGluR8 regulate transmission in the lateral olfactory tract-piriform cortex synapse. Jones PJ, Xiang Z, Conn PJ (2008) Neuropharmacology 55(4): 440-6
    › Primary publication · 18625254 (PubMed) · PMC2644556 (PubMed Central)
  227. Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold. Sharma S, Rodriguez AL, Conn PJ, Lindsley CW (2008) Bioorg Med Chem Lett 18(14): 4098-101
    › Primary publication · 18550372 (PubMed) · PMC2533619 (PubMed Central)
  228. MGluR5 mediates the interaction between late-LTP, network activity, and learning. Bikbaev A, Neyman S, Ngomba RT, Conn PJ, Conn J, Nicoletti F, Manahan-Vaughan D (2008) PLoS One 3(5): e2155
    › Primary publication · 18478073 (PubMed) · PMC2364645 (PubMed Central)
  229. Schizophrenia: moving beyond monoamine antagonists. Conn PJ, Tamminga C, Schoepp DD, Lindsley C (2008) Mol Interv 8(2): 99-107
    › Primary publication · 18403654 (PubMed)
  230. Group III mGluR regulation of synaptic transmission at the SC-CA1 synapse is developmentally regulated. Ayala JE, Niswender CM, Luo Q, Banko JL, Conn PJ (2008) Neuropharmacology 54(5): 804-14
    › Primary publication · 18255102 (PubMed) · PMC2431171 (PubMed Central)
  231. Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings. Conn PJ, Roth BL (2008) Neuropsychopharmacology 33(9): 2048-60
    › Primary publication · 18216778 (PubMed)
  232. Synthesis and SAR of selective muscarinic acetylcholine receptor subtype 1 (M1 mAChR) antagonists. Lewis LM, Sheffler D, Williams R, Bridges TM, Kennedy JP, Brogan JT, Mulder MJ, Williams L, Nalywajko NT, Niswender CM, Weaver CD, Conn PJ, Lindsley CW (2008) Bioorg Med Chem Lett 18(3): 885-90
    › Primary publication · 18178088 (PubMed) · PMC2275053 (PubMed Central)
  233. A novel assay of Gi/o-linked G protein-coupled receptor coupling to potassium channels provides new insights into the pharmacology of the group III metabotropic glutamate receptors. Niswender CM, Johnson KA, Luo Q, Ayala JE, Kim C, Conn PJ, Weaver CD (2008) Mol Pharmacol 73(4): 1213-24
    › Primary publication · 18171729 (PubMed)
  234. An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Shirey JK, Xiang Z, Orton D, Brady AE, Johnson KA, Williams R, Ayala JE, Rodriguez AL, Wess J, Weaver D, Niswender CM, Conn PJ (2008) Nat Chem Biol 4(1): 42-50
    › Primary publication · 18059262 (PubMed)
  235. N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors. Chen Y, Goudet C, Pin JP, Conn PJ (2008) Mol Pharmacol 73(3): 909-18
    › Primary publication · 18056795 (PubMed)
  236. D1- and D2-like dopamine receptors regulate signaling properties of group I metabotropic glutamate receptors in the rat globus pallidus. Poisik OV, Smith Y, Conn PJ (2007) Eur J Neurosci 26(4): 852-62
    › Primary publication · 17672856 (PubMed)
  237. A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Benneyworth MA, Xiang Z, Smith RL, Garcia EE, Conn PJ, Sanders-Bush E (2007) Mol Pharmacol 72(2): 477-84
    › Primary publication · 17526600 (PubMed)
  238. A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors. Hemstapat K, Da Costa H, Nong Y, Brady AE, Luo Q, Niswender CM, Tamagnan GD, Conn PJ (2007) J Pharmacol Exp Ther 322(1): 254-64
    › Primary publication · 17416742 (PubMed)
  239. Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses. Chen Y, Nong Y, Goudet C, Hemstapat K, de Paulis T, Pin JP, Conn PJ (2007) Mol Pharmacol 71(5): 1389-98
    › Primary publication · 17303702 (PubMed)
  240. Preclinical drug discovery research and training at Vanderbilt. Lindsley CW, Weaver D, Jones C, Marnett L, Conn PJ (2007) ACS Chem Biol 2(1): 17-20
    › Primary publication · 17243778 (PubMed)
  241. Challenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA. Zhao Z, Wisnoski DD, O'Brien JA, Lemaire W, Williams DL, Jacobson MA, Wittman M, Ha SN, Schaffhauser H, Sur C, Pettibone DJ, Duggan ME, Conn PJ, Hartman GD, Lindsley CW (2007) Bioorg Med Chem Lett 17(5): 1386-91
    › Primary publication · 17210250 (PubMed)
  242. Design, synthesis, and in vivo efficacy of glycine transporter-1 (GlyT1) inhibitors derived from a series of [4-phenyl-1-(propylsulfonyl)piperidin-4-yl]methyl benzamides. Lindsley CW, Zhao Z, Leister WH, O'Brien J, Lemaire W, Williams DL, Chen TB, Chang RS, Burno M, Jacobson MA, Sur C, Kinney GG, Pettibone DJ, Tiller PR, Smith S, Tsou NN, Duggan ME, Conn PJ, Hartman GD (2006) ChemMedChem 1(8): 807-11
    › Primary publication · 16902933 (PubMed)
  243. Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes. de Paulis T, Hemstapat K, Chen Y, Zhang Y, Saleh S, Alagille D, Baldwin RM, Tamagnan GD, Conn PJ (2006) J Med Chem 49(11): 3332-44
    › Primary publication · 16722652 (PubMed)
  244. A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators. Hemstapat K, de Paulis T, Chen Y, Brady AE, Grover VK, Alagille D, Tamagnan GD, Conn PJ (2006) Mol Pharmacol 70(2): 616-26
    › Primary publication · 16645124 (PubMed)
  245. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. Galici R, Jones CK, Hemstapat K, Nong Y, Echemendia NG, Williams LC, de Paulis T, Conn PJ (2006) J Pharmacol Exp Ther 318(1): 173-85
    › Primary publication · 16608916 (PubMed)
  246. mGluR7's lucky number. Conn PJ, Niswender CM (2006) Proc Natl Acad Sci U S A 103(2): 251-2
    › Primary publication · 16407154 (PubMed) · PMC1326193 (PubMed Central)
  247. Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors. Marino MJ, Conn PJ (2006) Curr Opin Pharmacol 6(1): 98-102
    › Primary publication · 16368268 (PubMed)
  248. Metabotropic glutamate receptors in the basal ganglia motor circuit. Conn PJ, Battaglia G, Marino MJ, Nicoletti F (2005) Nat Rev Neurosci 6(10): 787-98
    › Primary publication · 16276355 (PubMed)
  249. New therapeutic frontiers for metabotropic glutamate receptors. Niswender CM, Jones CK, Conn PJ (2005) Curr Top Med Chem 5(9): 847-57
    › Primary publication · 16178730 (PubMed)
  250. A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators. Rodriguez AL, Nong Y, Sekaran NK, Alagille D, Tamagnan GD, Conn PJ (2005) Mol Pharmacol 68(6): 1793-802
    › Primary publication · 16155210 (PubMed)
  251. Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. Zhang Y, Rodriguez AL, Conn PJ (2005) J Pharmacol Exp Ther 315(3): 1212-9
    › Primary publication · 16135701 (PubMed)
  252. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. Galici R, Echemendia NG, Rodriguez AL, Conn PJ (2005) J Pharmacol Exp Ther 315(3): 1181-7
    › Primary publication · 16123306 (PubMed)
  253. NMDA-induced potentiation of mGluR5 is mediated by activation of protein phosphatase 2B/calcineurin. Alagarsamy S, Saugstad J, Warren L, Mansuy IM, Gereau RW, Conn PJ (2005) Neuropharmacology : 135-45
    › Primary publication · 16005030 (PubMed) · PMC3799794 (PubMed Central)
  254. Metabotropic glutamate receptor 2 modulates excitatory synaptic transmission in the rat globus pallidus. Poisik O, Raju DV, Verreault M, Rodriguez A, Abeniyi OA, Conn PJ, Smith Y (2005) Neuropharmacology : 57-69
    › Primary publication · 15993439 (PubMed)
  255. Group III metabotropic glutamate-receptor-mediated modulation of excitatory transmission in rodent substantia nigra pars compacta dopamine neurons. Valenti O, Mannaioni G, Seabrook GR, Conn PJ, Marino MJ (2005) J Pharmacol Exp Ther 313(3): 1296-304
    › Primary publication · 15761115 (PubMed)
  256. Clozapine potentiation of N-methyl-D-aspartate receptor currents in the nucleus accumbens: role of NR2B and protein kinase A/Src kinases. Wittmann M, Marino MJ, Henze DA, Seabrook GR, Conn PJ (2005) J Pharmacol Exp Ther 313(2): 594-603
    › Primary publication · 15659539 (PubMed)
  257. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. Kinney GG, O'Brien JA, Lemaire W, Burno M, Bickel DJ, Clements MK, Chen TB, Wisnoski DD, Lindsley CW, Tiller PR, Smith S, Jacobson MA, Sur C, Duggan ME, Pettibone DJ, Conn PJ, Williams DL (2005) J Pharmacol Exp Ther 313(1): 199-206
    › Primary publication · 15608073 (PubMed)
  258. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo. Lindsley CW, Wisnoski DD, Leister WH, O'brien JA, Lemaire W, Williams DL, Burno M, Sur C, Kinney GG, Pettibone DJ, Tiller PR, Smith S, Duggan ME, Hartman GD, Conn PJ, Huff JR (2004) J Med Chem 47(24): 5825-8
    › Primary publication · 15537338 (PubMed)
  259. Metabotropic glutamate receptors modulate feedback inhibition in a developmentally regulated manner in rat dentate gyrus. Doherty JJ, Alagarsamy S, Bough KJ, Conn PJ, Dingledine R, Mott DD (2004) J Physiol 561(Pt 2): 395-401
    › Primary publication · 15513941 (PubMed) · PMC1665349 (PubMed Central)
  260. Effects of typical and atypical antipsychotics on human glycine transporters. Williams JB, Mallorga PJ, Conn PJ, Pettibone DJ, Sur C (2004) Schizophr Res 71(1): 103-12
    › Primary publication · 15374578 (PubMed)
  261. The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats. Campbell UC, Lalwani K, Hernandez L, Kinney GG, Conn PJ, Bristow LJ (2004) Psychopharmacology (Berl) 175(3): 310-8
    › Primary publication · 15024550 (PubMed)
  262. A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. O'Brien JA, Lemaire W, Wittmann M, Jacobson MA, Ha SN, Wisnoski DD, Lindsley CW, Schaffhauser HJ, Rowe B, Sur C, Duggan ME, Pettibone DJ, Conn PJ, Williams DL (2004) J Pharmacol Exp Ther 309(2): 568-77
    › Primary publication · 14747613 (PubMed)
  263. Difference in mGluR5 interaction between positive allosteric modulators from two structural classes. Williams DL, O'Brien JA, Lemaire W, Chen TB, Chang RS, Jacobson MA, Ha SN, Wisnoski DD, Lindsley CW, Sur C, Duggan ME, Pettibone DJ, Conn PJ (2003) Ann N Y Acad Sci : 481-4
    › Primary publication · 14684495 (PubMed)
  264. Modulation of excitatory transmission onto midbrain dopaminergic neurons of the rat by activation of group III metabotropic glutamate receptors. Valenti O, Marino MJ, Conn PJ (2003) Ann N Y Acad Sci : 479-80
    › Primary publication · 14684494 (PubMed)
  265. Modulation of inhibitory transmission in the rat globus pallidus by activation of mGluR4. Marino MJ, Valenti O, O'Brien JA, Williams DL, Conn PJ (2003) Ann N Y Acad Sci : 435-7
    › Primary publication · 14684481 (PubMed)
  266. Physiological roles and therapeutic potential of metabotropic glutamate receptors. Conn PJ (2003) Ann N Y Acad Sci : 12-21
    › Primary publication · 14684432 (PubMed)
  267. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB, Brandish PE, Pettibone DJ, Scolnick EM, Conn PJ (2003) Proc Natl Acad Sci U S A 100(23): 13674-9
    › Primary publication · 14595031 (PubMed) · PMC263872 (PubMed Central)
  268. Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Marino MJ, Williams DL, O'Brien JA, Valenti O, McDonald TP, Clements MK, Wang R, DiLella AG, Hess JF, Kinney GG, Conn PJ (2003) Proc Natl Acad Sci U S A 100(23): 13668-73
    › Primary publication · 14593202 (PubMed) · PMC263871 (PubMed Central)
  269. The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia. Junge CE, Sugawara T, Mannaioni G, Alagarsamy S, Conn PJ, Brat DJ, Chan PH, Traynelis SF (2003) Proc Natl Acad Sci U S A 100(22): 13019-24
    › Primary publication · 14559973 (PubMed) · PMC240737 (PubMed Central)
  270. Development of a scintillation proximity assay for analysis of Na+/Cl- -dependent neurotransmitter transporter activity. Williams JB, Mallorga PJ, Lemaire W, Williams DL, Na S, Patel S, Conn PJ, Conn JP, Pettibone DJ, Austin C, Sur C (2003) Anal Biochem 321(1): 31-7
    › Primary publication · 12963052 (PubMed)
  271. Pharmacology and expression analysis of glycine transporter GlyT1 with [3H]-(N-[3-(4'-fluorophenyl)-3-(4'phenylphenoxy)propyl])sarcosine. Mallorga PJ, Williams JB, Jacobson M, Marques R, Chaudhary A, Conn PJ, Pettibone DJ, Sur C (2003) Neuropharmacology 45(5): 585-93
    › Primary publication · 12941372 (PubMed)
  272. The glycine transporter type 1 inhibitor N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. Kinney GG, Sur C, Burno M, Mallorga PJ, Williams JB, Figueroa DJ, Wittmann M, Lemaire W, Conn PJ (2003) J Neurosci 23(20): 7586-91
    › Primary publication · 12930797 (PubMed)
  273. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. O'Brien JA, Lemaire W, Chen TB, Chang RS, Jacobson MA, Ha SN, Lindsley CW, Schaffhauser HJ, Sur C, Pettibone DJ, Conn PJ, Williams DL (2003) Mol Pharmacol 64(3): 731-40
    › Primary publication · 12920211 (PubMed)
  274. Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse. Valenti O, Marino MJ, Wittmann M, Lis E, DiLella AG, Kinney GG, Conn PJ (2003) J Neurosci 23(18): 7218-26
    › Primary publication · 12904482 (PubMed)
  275. Direct and indirect modulation of the N-methyl D-aspartate receptor. Marino MJ, Conn PJ (2002) Curr Drug Targets CNS Neurol Disord 1(1): 1-16
    › Primary publication · 12769631 (PubMed)
  276. Modulation of the basal ganglia by metabotropic glutamate receptors: potential for novel therapeutics. Marino MJ, Conn PJ, Conn JP (2002) Curr Drug Targets CNS Neurol Disord 1(3): 239-50
    › Primary publication · 12769617 (PubMed)
  277. Glutamate receptors and Parkinson's disease: opportunities for intervention. Marino MJ, Valenti O, Conn PJ (2003) Drugs Aging 20(5): 377-97
    › Primary publication · 12696997 (PubMed)
  278. G protein-coupled receptor kinases regulate metabotropic glutamate receptor 5 function and expression. Sorensen SD, Conn PJ (2003) Neuropharmacology 44(6): 699-706
    › Primary publication · 12681368 (PubMed)
  279. Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. Kinney GG, Burno M, Campbell UC, Hernandez LM, Rodriguez D, Bristow LJ, Conn PJ (2003) J Pharmacol Exp Ther 306(1): 116-23
    › Primary publication · 12660307 (PubMed)
  280. Distinct functional roles of the metabotropic glutamate receptors 1 and 5 in the rat globus pallidus. Poisik OV, Mannaioni G, Traynelis S, Smith Y, Conn PJ (2003) J Neurosci 23(1): 122-30
    › Primary publication · 12514208 (PubMed)
  281. Metabotropic glutamate receptors. Schoepp DD, Conn PJ (2002) Pharmacol Biochem Behav 74(1): 255-6
    › Primary publication · 12376174 (PubMed)
  282. Localization and physiological roles of metabotropic glutamate receptors in the direct and indirect pathways of the basal ganglia. Marino MJ, Awad H, Poisik O, Wittmann M, Conn PJ (2002) Amino Acids 23(1-3): 185-91
    › Primary publication · 12373536 (PubMed)
  283. Differential regulation of metabotropic glutamate receptor 5-mediated phosphoinositide hydrolysis and extracellular signal-regulated kinase responses by protein kinase C in cultured astrocytes. Peavy RD, Sorensen SD, Conn PJ (2002) J Neurochem 83(1): 110-8
    › Primary publication · 12358734 (PubMed)
  284. Haloperidol-induced alteration in the physiological actions of group I mGlus in the subthalamic nucleus and the substantia nigra pars reticulata. Marino MJ, Awad-Granko H, Ciombor KJ, Conn PJ (2002) Neuropharmacology 43(2): 147-59
    › Primary publication · 12213269 (PubMed)
  285. Dopamine modulates the function of group II and group III metabotropic glutamate receptors in the substantia nigra pars reticulata. Wittmann M, Marino MJ, Conn PJ (2002) J Pharmacol Exp Ther 302(2): 433-41
    › Primary publication · 12130700 (PubMed)
  286. NMDA-induced phosphorylation and regulation of mGluR5. Alagarsamy S, Rouse ST, Junge C, Hubert GW, Gutman D, Smith Y, Conn PJ (2002) Pharmacol Biochem Behav 73(2): 299-306
    › Primary publication · 12117583 (PubMed)
  287. Activation of group III metabotropic glutamate receptors inhibits the production of RANTES in glial cell cultures. Besong G, Battaglia G, D'Onofrio M, Di Marco R, Ngomba RT, Storto M, Castiglione M, Mangano K, Busceti CL, Nicoletti FR, Bacon K, Tusche M, Valenti O, Conn PJ, Bruno V, Nicoletti F (2002) J Neurosci 22(13): 5403-11
    › Primary publication · 12097492 (PubMed)
  288. Distinct physiological roles of the Gq-coupled metabotropic glutamate receptors Co-expressed in the same neuronal populations. Valenti O, Conn PJ, Marino MJ (2002) J Cell Physiol 191(2): 125-37
    › Primary publication · 12064455 (PubMed)
  289. Dissociation of protein kinase-mediated regulation of metabotropic glutamate receptor 7 (mGluR7) interactions with calmodulin and regulation of mGluR7 function. Sorensen SD, Macek TA, Cai Z, Saugstad JA, Conn PJ (2002) Mol Pharmacol 61(6): 1303-12
    › Primary publication · 12021391 (PubMed)
  290. Interaction between metabotropic glutamate receptor 7 and alpha tubulin. Saugstad JA, Yang S, Pohl J, Hall RA, Conn PJ (2002) J Neurochem 80(6): 980-8
    › Primary publication · 11953448 (PubMed) · PMC2925652 (PubMed Central)
  291. Metabotropic glutamate receptor 5-induced phosphorylation of extracellular signal-regulated kinase in astrocytes depends on transactivation of the epidermal growth factor receptor. Peavy RD, Chang MS, Sanders-Bush E, Conn PJ (2001) J Neurosci 21(24): 9619-28
    › Primary publication · 11739572 (PubMed)
  292. Activation of group I metabotropic glutamate receptors produces a direct excitation and disinhibition of GABAergic projection neurons in the substantia nigra pars reticulata. Marino MJ, Wittmann M, Bradley SR, Hubert GW, Smith Y, Conn PJ (2001) J Neurosci 21(18): 7001-12
    › Primary publication · 11549710 (PubMed)
  293. Activation of metabotropic glutamate receptor 1 inhibits glutamatergic transmission in the substantia nigra pars reticulata. Wittmann M, Hubert GW, Smith Y, Conn PJ (2001) Neuroscience 105(4): 881-9
    › Primary publication · 11530226 (PubMed)
  294. Allosteric interaction between the amino terminal domain and the ligand binding domain of NR2A. Zheng F, Erreger K, Low CM, Banke T, Lee CJ, Conn PJ, Traynelis SF (2001) Nat Neurosci 4(9): 894-901
    › Primary publication · 11528420 (PubMed)
  295. Cyclic AMP-dependent protein kinase phosphorylates group III metabotropic glutamate receptors and inhibits their function as presynaptic receptors. Cai Z, Saugstad JA, Sorensen SD, Ciombor KJ, Zhang C, Schaffhauser H, Hubalek F, Pohl J, Duvoisin RM, Conn PJ (2001) J Neurochem 78(4): 756-66
    › Primary publication · 11520896 (PubMed) · PMC3799790 (PubMed Central)
  296. Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function. Mannaioni G, Marino MJ, Valenti O, Traynelis SF, Conn PJ (2001) J Neurosci 21(16): 5925-34
    › Primary publication · 11487615 (PubMed)
  297. Activation of groups I or III metabotropic glutamate receptors inhibits excitatory transmission in the rat subthalamic nucleus. Awad-Granko H, Conn PJ (2001) Neuropharmacology 41(1): 32-41
    › Primary publication · 11445183 (PubMed)
  298. Coordinate regulation of metabotropic glutamate receptors. Alagarsamy S, Sorensen SD, Conn PJ (2001) Curr Opin Neurobiol 11(3): 357-62
    › Primary publication · 11399435 (PubMed)
  299. Activation of group III mGluRs inhibits GABAergic and glutamatergic transmission in the substantia nigra pars reticulata. Wittmann M, Marino MJ, Bradley SR, Conn PJ (2001) J Neurophysiol 85(5): 1960-8
    › Primary publication · 11353013 (PubMed)
  300. Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders. Rouse ST, Marino MJ, Bradley SR, Awad H, Wittmann M, Conn PJ (2000) Pharmacol Ther 88(3): 427-35
    › Primary publication · 11337032 (PubMed)
  301. Molecular determinants of metabotropic glutamate receptor signaling. De Blasi A, Conn PJ, Pin J, Nicoletti F (2001) Trends Pharmacol Sci 22(3): 114-20
    › Primary publication · 11239574 (PubMed)
  302. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. Awad H, Hubert GW, Smith Y, Levey AI, Conn PJ (2000) J Neurosci 20(21): 7871-9
    › Primary publication · 11050106 (PubMed)
  303. Functional downregulation of GluR2 in piriform cortex of kindled animals. Prince HC, Tzingounis AV, Levey AI, Conn PJ (2000) Synapse 38(4): 489-98
    › Primary publication · 11044897 (PubMed)
  304. cAMP-dependent protein kinase inhibits mGluR2 coupling to G-proteins by direct receptor phosphorylation. Schaffhauser H, Cai Z, Hubalek F, Macek TA, Pohl J, Murphy TJ, Conn PJ (2000) J Neurosci 20(15): 5663-70
    › Primary publication · 10908604 (PubMed)
  305. Activation of group II metabotropic glutamate receptors inhibits synaptic excitation of the substantia Nigra pars reticulata. Bradley SR, Marino MJ, Wittmann M, Rouse ST, Awad H, Levey AI, Conn PJ (2000) J Neurosci 20(9): 3085-94
    › Primary publication · 10777772 (PubMed)
  306. Peripheral glutamate receptors: molecular biology and role in taste sensation. Dingledine R, Conn PJ (2000) J Nutr 130(4S Suppl): 1039S-42S
    › Primary publication · 10736377 (PubMed)
  307. Muscarinic-induced modulation of potassium conductances is unchanged in mouse hippocampal pyramidal cells that lack functional M1 receptors. Rouse ST, Hamilton SE, Potter LT, Nathanson NM, Conn PJ (2000) Neurosci Lett 278(1-2): 61-4
    › Primary publication · 10643801 (PubMed)
  308. Up-regulation of the metabotropic glutamate receptor mGluR4 in hippocampal neurons with reduced seizure vulnerability. Lie AA, Becker A, Behle K, Beck H, Malitschek B, Conn PJ, Kuhn R, Nitsch R, Plaschke M, Schramm J, Elger CE, Wiestler OD, Blümcke I (2000) Ann Neurol 47(1): 26-35
    › Primary publication · 10632098 (PubMed)
  309. Fragile X mouse: strain effects of knockout phenotype and evidence suggesting deficient amygdala function. Paradee W, Melikian HE, Rasmussen DL, Kenneson A, Conn PJ, Warren ST (1999) Neuroscience 94(1): 185-92
    › Primary publication · 10613508 (PubMed)
  310. Localization of metabotropic glutamate receptor 7 mRNA and mGluR7a protein in the rat basal ganglia. Kosinski CM, Risso Bradley S, Conn PJ, Levey AI, Landwehrmeyer GB, Penney JB, Young AB, Standaert DG (1999) J Comp Neurol 415(2): 266-84
    › Primary publication · 10545164 (PubMed)
  311. Activation of PKC disrupts presynaptic inhibition by group II and group III metabotropic glutamate receptors and uncouples the receptor from GTP-binding proteins. Macek TA, Schaffhauser H, Conn PJ (1999) Ann N Y Acad Sci : 554-7
    › Primary publication · 10414335 (PubMed)
  312. Distribution of group III mGluRs in rat basal ganglia with subtype-specific antibodies. Bradley SR, Standaert DG, Levey AI, Conn PJ (1999) Ann N Y Acad Sci : 531-4
    › Primary publication · 10414330 (PubMed)
  313. Activation of N-methyl-D-aspartate receptors reverses desensitization of metabotropic glutamate receptor, mGluR5, in native and recombinant systems. Alagarsamy S, Rouse ST, Gereau RW, Heinemann SF, Smith Y, Conn PJ (1999) Ann N Y Acad Sci : 526-30
    › Primary publication · 10414329 (PubMed)
  314. Immunohistochemical localization of subtype 4a metabotropic glutamate receptors in the rat and mouse basal ganglia. Bradley SR, Standaert DG, Rhodes KJ, Rees HD, Testa CM, Levey AI, Conn PJ (1999) J Comp Neurol 407(1): 33-46
    › Primary publication · 10213186 (PubMed)
  315. Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems. Alagarsamy S, Marino MJ, Rouse ST, Gereau RW, Heinemann SF, Conn PJ (1999) Nat Neurosci 2(3): 234-40
    › Primary publication · 10195215 (PubMed)
  316. Tyrosine kinase potentiates NMDA receptor currents by reducing tonic zinc inhibition. Zheng F, Gingrich MB, Traynelis SF, Conn PJ (1998) Nat Neurosci 1(3): 185-91
    › Primary publication · 10195142 (PubMed)
  317. Muscarinic receptor subtypes involved in hippocampal circuits. Rouse ST, Marino MJ, Potter LT, Conn PJ, Levey AI (1999) Life Sci 64(6-7): 501-9
    › Primary publication · 10069516 (PubMed)
  318. Heterogeneity of metabotropic glutamate receptors in autonomic cell groups of the medulla oblongata of the rat. Hay M, McKenzie H, Lindsley K, Dietz N, Bradley SR, Conn PJ, Hasser EM (1999) J Comp Neurol 403(4): 486-501
    › Primary publication · 9888314 (PubMed)
  319. Immunohistochemical distribution of RGS7 protein and cellular selectivity in colocalizing with Galphaq proteins in the adult rat brain. Khawaja XZ, Liang JJ, Saugstad JA, Jones PG, Harnish S, Conn PJ, Cockett MI (1999) J Neurochem 72(1): 174-84
    › Primary publication · 9886068 (PubMed)
  320. Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. Marino MJ, Rouse ST, Levey AI, Potter LT, Conn PJ (1998) Proc Natl Acad Sci U S A 95(19): 11465-70
    › Primary publication · 9736760 (PubMed) · PMC21666 (PubMed Central)
  321. Protein kinase C and A3 adenosine receptor activation inhibit presynaptic metabotropic glutamate receptor (mGluR) function and uncouple mGluRs from GTP-binding proteins. Macek TA, Schaffhauser H, Conn PJ (1998) J Neurosci 18(16): 6138-46
    › Primary publication · 9698308 (PubMed)
  322. Distribution and developmental regulation of metabotropic glutamate receptor 7a in rat brain. Bradley SR, Rees HD, Yi H, Levey AI, Conn PJ (1998) J Neurochem 71(2): 636-45
    › Primary publication · 9681454 (PubMed)
  323. Phosphorylation of mitogen-activated protein kinase in cultured rat cortical glia by stimulation of metabotropic glutamate receptors. Peavy RD, Conn PJ (1998) J Neurochem 71(2): 603-12
    › Primary publication · 9681450 (PubMed)
  324. RGS4 inhibits signaling by group I metabotropic glutamate receptors. Saugstad JA, Marino MJ, Folk JA, Hepler JR, Conn PJ (1998) J Neurosci 18(3): 905-13
    › Primary publication · 9437012 (PubMed)
  325. 4-Methylhomoibotenic acid activates a novel metabotropic glutamate receptor coupled to phosphoinositide hydrolysis. Chung DS, Traynelis SF, Murphy TJ, Conn PJ (1997) J Pharmacol Exp Ther 283(2): 742-9
    › Primary publication · 9353394 (PubMed)
  326. Pharmacology and functions of metabotropic glutamate receptors. Conn PJ, Pin JP (1997) Annu Rev Pharmacol Toxicol : 205-37
    › Primary publication · 9131252 (PubMed)
  327. Alterations in glutamate transporter protein levels in kindling-induced epilepsy. Miller HP, Levey AI, Rothstein JD, Tzingounis AV, Conn PJ (1997) J Neurochem 68(4): 1564-70
    › Primary publication · 9084427 (PubMed)
  328. Differential involvement of group II and group III mGluRs as autoreceptors at lateral and medial perforant path synapses. Macek TA, Winder DG, Gereau RW, Ladd CO, Conn PJ (1996) J Neurophysiol 76(6): 3798-806
    › Primary publication · 8985877 (PubMed)
  329. Roles of metabotropic glutamate receptors in glial function and glial-neuronal communication. Winder DG, Conn PJ (1996) J Neurosci Res 46(2): 131-7
    › Primary publication · 8915890 (PubMed)
  330. Novel glial-neuronal signalling by coactivation of metabotropic glutamate and beta-adrenergic receptors in rat hippocampus. Winder DG, Ritch PS, Gereau RW, Conn PJ (1996) J Physiol : 743-55
    › Primary publication · 8865071 (PubMed) · PMC1160674 (PubMed Central)
  331. Immunocytochemical localization of group III metabotropic glutamate receptors in the hippocampus with subtype-specific antibodies. Bradley SR, Levey AI, Hersch SM, Conn PJ (1996) J Neurosci 16(6): 2044-56
    › Primary publication · 8604049 (PubMed)
  332. Pharmacological differentiation of metabotropic glutamate receptors coupled to potentiation of cyclic adenosine monophosphate responses and phosphoinositide hydrolysis. Winder DG, Smith T, Conn PJ (1993) J Pharmacol Exp Ther 266(2): 518-25
    › Primary publication · 8394908 (PubMed)
  333. Activation of metabotropic glutamate receptors increases cAMP accumulation in hippocampus by potentiating responses to endogenous adenosine. Winder DG, Conn PJ (1993) J Neurosci 13(1): 38-44
    › Primary publication · 8380851 (PubMed)
  334. 4-Bromohomoibotenic acid selectively activates a 1-aminocyclopentane-1S,3R-dicarboxylic acid-insensitive metabotropic glutamate receptor coupled to phosphoinositide hydrolysis in rat cortical slices. Chung DS, Winder DG, Conn PJ (1994) J Neurochem 63(1): 133-9
    › Primary publication · 8207423 (PubMed)
  335. Potentiation of cAMP responses by metabotropic glutamate receptors depresses excitatory synaptic transmission by a kinase-independent mechanism. Gereau RW, Conn PJ (1994) Neuron 12(5): 1121-9
    › Primary publication · 8185947 (PubMed)
  336. A cyclic AMP-dependent form of associative synaptic plasticity induced by coactivation of beta-adrenergic receptors and metabotropic glutamate receptors in rat hippocampus. Gereau RW, Conn PJ (1994) J Neurosci 14(5 Pt 2): 3310-8
    › Primary publication · 8182474 (PubMed)
  337. L-cysteine sulfinic acid as an endogenous agonist of a novel metabotropic receptor coupled to stimulation of phospholipase D activity. Boss V, Nutt KM, Conn PJ (1994) Mol Pharmacol 45(6): 1177-82
    › Primary publication · 8022410 (PubMed)
  338. Metabotropic glutamate receptor-induced disinhibition is mediated by reduced transmission at excitatory synapses onto interneurons and inhibitory synapses onto pyramidal cells. Desai MA, McBain CJ, Kauer JA, Conn PJ (1994) Neurosci Lett 181(1-2): 78-82
    › Primary publication · 7898776 (PubMed)
  339. Metabotropic glutamate receptor (mGluR)-mediated potentiation of cyclic AMP responses does not require phosphoinositide hydrolysis: mediation by a group II-like mGluR. Winder DG, Conn PJ (1995) J Neurochem 64(2): 592-9
    › Primary publication · 7830052 (PubMed)
  340. Presynaptic enhancement of excitatory synaptic transmission by beta-adrenergic receptor activation. Gereau RW, Conn PJ (1994) J Neurophysiol 72(3): 1438-42
    › Primary publication · 7807226 (PubMed)
  341. Down-regulation of AMPA receptor subunit GluR2 in amygdaloid kindling. Prince HK, Conn PJ, Blackstone CD, Huganir RL, Levey AI (1995) J Neurochem 64(1): 462-5
    › Primary publication · 7798948 (PubMed)
  342. Pharmacological differentiation of the effects of co-activation of beta-adrenergic and metabotropic glutamate receptors in rat hippocampus. Gereau RW, Winder DG, Conn PJ (1995) Neurosci Lett 186(2-3): 119-22
    › Primary publication · 7777178 (PubMed)
  343. Metabotropic glutamate receptors in brain function and pathology. Schoepp DD, Conn PJ (1993) Trends Pharmacol Sci 14(1): 13-20
    › Primary publication · 7680175 (PubMed)
  344. Multiple presynaptic metabotropic glutamate receptors modulate excitatory and inhibitory synaptic transmission in hippocampal area CA1. Gereau RW, Conn PJ (1995) J Neurosci 15(10): 6879-89
    › Primary publication · 7472445 (PubMed)
  345. Roles of specific metabotropic glutamate receptor subtypes in regulation of hippocampal CA1 pyramidal cell excitability. Gereau RW, Conn PJ (1995) J Neurophysiol 74(1): 122-9
    › Primary publication · 7472317 (PubMed)
  346. Selective 5HT-2 antagonists inhibit serotonin stimulated phosphatidylinositol metabolism in cerebral cortex. Conn PJ, Sanders-Bush E (1984) Neuropharmacology 23(8): 993-6
    › Primary publication · 6483122 (PubMed)
  347. Denervation supersensitivity of 5-HT-1c receptors in rat choroid plexus. Conn PJ, Janowsky A, Sanders-Bush E (1987) Brain Res 400(2): 396-8
    › Primary publication · 3815085 (PubMed)
  348. Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. Conn PJ, Sanders-Bush E (1987) J Pharmacol Exp Ther 242(2): 552-7
    › Primary publication · 3039120 (PubMed)
  349. Effector systems coupled to serotonin receptors in brain: serotonin stimulated phosphoinositide hydrolysis. Sanders-Bush E, Conn PJ (1986) Psychopharmacol Bull 22(3): 829-36
    › Primary publication · 3025911 (PubMed)
  350. Regulation of serotonin-stimulated phosphoinositide hydrolysis: relation to the serotonin 5-HT-2 binding site. Conn PJ, Sanders-Bush E (1986) J Neurosci 6(12): 3669-75
    › Primary publication · 3025382 (PubMed)
  351. Agonist-induced phosphoinositide hydrolysis in choroid plexus. Conn PJ, Sanders-Bush E (1986) J Neurochem 47(6): 1754-60
    › Primary publication · 3021903 (PubMed)
  352. Biochemical characterization of serotonin stimulated phosphoinositide turnover. Conn PJ, Sanders-Bush E (1986) Life Sci 38(7): 663-9
    › Primary publication · 3003490 (PubMed)
  353. Serotonin-stimulated phosphoinositide turnover: mediation by the S2 binding site in rat cerebral cortex but not in subcortical regions. Conn PJ, Sanders-Bush E (1985) J Pharmacol Exp Ther 234(1): 195-203
    › Primary publication · 2989504 (PubMed)
  354. A unique serotonin receptor in choroid plexus is linked to phosphatidylinositol turnover. Conn PJ, Sanders-Bush E, Hoffman BJ, Hartig PR (1986) Proc Natl Acad Sci U S A 83(11): 4086-8
    › Primary publication · 2940597 (PubMed) · PMC323671 (PubMed Central)
  355. Inhibitors of protein kinase C prevent enhancement of calcium current and action potentials in peptidergic neurons of Aplysia. Conn PJ, Strong JA, Kaczmarek LK (1989) J Neurosci 9(2): 480-7
    › Primary publication · 2918372 (PubMed)
  356. Central serotonin receptors: effector systems, physiological roles and regulation. Conn PJ, Sanders-Bush E (1987) Psychopharmacology (Berl) 92(3): 267-77
    › Primary publication · 2819915 (PubMed)
  357. The bag cell neurons of Aplysia. A model for the study of the molecular mechanisms involved in the control of prolonged animal behaviors. Conn PJ, Kaczmarek LK (1989) Mol Neurobiol 3(4): 237-73
    › Primary publication · 2698177 (PubMed)
  358. Protein kinase inhibitors selectively block phorbol ester- or forskolin-induced changes in excitability of Aplysia neurons. Conn PJ, Strong JA, Azhderian EM, Nairn AC, Greengard P, Kaczmarek LK (1989) J Neurosci 9(2): 473-9
    › Primary publication · 2537389 (PubMed)
  359. Selective activation of phosphoinositide hydrolysis by a rigid analogue of glutamate. Desai MA, Conn PJ (1990) Neurosci Lett 109(1-2): 157-62
    › Primary publication · 1969130 (PubMed)
  360. Excitatory effects of ACPD receptor activation in the hippocampus are mediated by direct effects on pyramidal cells and blockade of synaptic inhibition. Desai MA, Conn PJ (1991) J Neurophysiol 66(1): 40-52
    › Primary publication · 1655995 (PubMed)
  361. Metabotropic excitatory amino acid receptor activation stimulates phospholipase D in hippocampal slices. Boss V, Conn PJ (1992) J Neurochem 59(6): 2340-3
    › Primary publication · 1431912 (PubMed)
  362. Amygdala kindling alters protein kinase C activity in dentate gyrus. Chen SJ, Desai MA, Klann E, Winder DG, Sweatt JD, Conn PJ (1992) J Neurochem 59(5): 1761-9
    › Primary publication · 1402921 (PubMed)
  363. Trans-ACPD-induced phosphoinositide hydrolysis and modulation of hippocampal pyramidal cell excitability do not undergo parallel developmental regulation. Boss V, Desai MA, Smith TS, Conn PJ (1992) Brain Res 594(2): 181-8
    › Primary publication · 1360322 (PubMed)
  364. Activation of metabotropic glutamate receptors in the hippocampus increases cyclic AMP accumulation. Winder DG, Conn PJ (1992) J Neurochem 59(1): 375-8
    › Primary publication · 1351930 (PubMed)
  365. Multiple metabotropic glutamate receptors regulate hippocampal function. Desai MA, Smith TS, Conn PJ (1992) Synapse 12(3): 206-13
    › Primary publication · 1336225 (PubMed)